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Abstract 28 
 2 
Growth failure is frequently encountered in children with chronic inflammatory conditions 29 
like juvenile idiopathic arthritis, inflammatory bowel disease and cystic fibrosis. Delayed 30 
puberty and attenuated pubertal growth spurt is often seen during adolescence. The 31 
underlying inflammatory state mediated by pro-inflammatory cytokines, prolonged use of 32 
glucocorticoid and suboptimal nutrition contribute to growth failure and pubertal 33 
abnormalities. These factors can impair growth by their effects on the growth hormone-34 
insulin like growth factor axis and also directly at the level of the growth plate via alterations 35 
in chondrogenesis and local growth factor signaling. Recent studies on the impact of 36 
cytokines and glucocorticoid on the growth plate studies further advanced our understanding 37 
of growth failure in chronic disease and provided a biological rationale of growth promotion. 38 
Targeting cytokines using biologic therapy may lead to improvement of growth in some of 39 
these children but approximately one third continue to grow slowly. There is increasing 40 
evidence that the use of relatively high dose recombinant human growth hormone may lead to 41 
partial catch up growth in chronic inflammatory conditions, although long term follow-up 42 
data is currently limited. In this review, we comprehensively review the growth abnormalities 43 
in children with juvenile idiopathic arthritis, inflammatory bowel disease and cystic fibrosis, 44 
systemic abnormalities of the growth hormone-insulin like growth factor axis and growth 45 
plate perturbations. We also systematically reviewed all the current published studies of 46 
recombinant human growth hormone in these conditions and discuss the role of recombinant 47 
human insulin like growth factor-1.  48 
 49 
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1.  Introduction 137 
Impaired linear growth is commonly encountered in children with chronic inflammatory 138 
conditions such as juvenile idiopathic arthritis (JIA) (1)  inflammatory bowel disease (IBD), 139 
especially those with Crohn’s disease (CD) (2,3) and cystic fibrosis (CF) (4,5). This may be 140 
associated with delayed onset of puberty and attenuated pubertal growth spurt (6), especially 141 
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in those with IBD as these children tend to present in late childhood and adolescence [Figure 142 
1]. Poor growth may lead to short stature and a reduction in adult height is seen in a sub set of 143 
these patients despite contemporary medical therapy (7-9) which may have an impact on their 144 
quality of life (10). 145 
Sub-optimal nutrition, prolonged use of glucocorticoid (GC) and chronic 146 
inflammation itself contribute to the underlying pathophysiology of growth failure (11,12). 147 
This may be through effects on the systemic growth hormone (GH) axis that regulates linear 148 
growth or through direct effects at the level of the growth plate (13) [Figure 2]. Chronic 149 
inflammation may lead to a continuum of abnormalities in the systemic GH/ insulin like 150 
growth factor-1 (IGF-1) axis including relative GH insufficiency, GH/IGF-1 resistance due to 151 
impairment of IGF binding proteins, down regulation of GH/IGF receptors and / or 152 
impairment of local GH and IGF-1 signaling pathways [Figure 3].  153 
Determining the prevalence of growth failure from current published studies in 154 
children with JIA, IBD and CF is very challenging due to the different definitions used. 155 
Studies defining growth failure based on stature are not helpful, as this may underestimate the 156 
prevalence of faltering growth, given that a child with relatively normal height may have been 157 
growing very poorly over a period of time. Stature also needs to be interpreted in the context 158 
of the child’s mid-parental height.  159 
Evaluating growth rate (height velocity) maybe a better method to determine the 160 
prevalence of growth failure but in a group of children where a degree of delayed puberty 161 
maybe relatively common, comparing height velocity (HV) purely based on age and gender 162 
may be misleading. Due to the unpredictability of the inflammatory process, HV is also likely 163 
to vary depending on the disease status rather than time course from diagnosis compared to 164 
other conditions where treatment protocols may be fixed (eg childhood cancers). HV needs to 165 
be interpreted in the context of pubertal staging or bone age as it varies according to gender 166 
and pubertal status (14). In healthy girls, peak HV is attained at the age of approximately 12 167 
years, corresponding to early breast stage (stage 2) whereas in healthy boys this is usually at 168 
the age of 13.5 years corresponding to later stages of puberty (genital stage 4, 10-12 ml testes) 169 
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(15,16).  There is no consensus regarding the most appropriate method to interpret HV in 170 
these children. In addition, normative data for HV are from small groups of children evaluated 171 
in the 70s.  172 
Consideration must be given to bone age assessment in children with chronic disease. 173 
Interpretation of bone age may be inaccurate if performed in the hand affected by arthritis 174 
(17). The use of change in height (Ht) SDS maybe a better method of defining growth 175 
problems in longitudinal growth studies in children with chronic disease as recently suggested 176 
as a way to report response to growth promoting therapy (18) but may also need to be 177 
interpreted in the context of puberty and/or skeletal maturation for adolescents. 178 
Targeting the inflammatory process aggressively using immunomodulators (eg 179 
azathioprine, methotrexate) and anti-cytokine therapy (eg infliximab, etanercept, 180 
adalimumab), minimizing the use of systemic GC to achieve adequate control of 181 
inflammation and optimizing nutrition may be associated with improvement in markers of the 182 
GH-IGF axis and are paramount for ensuring normal growth and pubertal development 183 
(19,20). However, almost one third of children with JIA and CD treated with contemporary 184 
regimens continue to grow slowly (18) and improvement in disease activity does not seem to 185 
normalize linear growth in these children (21,22). In adolescents with CF, faltering growth 186 
often precedes the diagnosis of CF related diabetes (23). Whilst treatment with insulin may 187 
improve lung function and body mass index (BMI) in children with CF related diabetes 188 
(24,25), the impact of insulin on improving growth and pubertal development is still unclear 189 
(23). In an individual with CF and faltering growth, assessment of glucose homeostasis 190 
should be performed to exclude CF diabetes. Optimization of metabolic control with insulin 191 
should be performed in those already with established CF related diabetes and poor growth.  192 
Pubertal induction with sex steroid may be considered in those individuals who are 193 
growing slowly in association with delayed puberty despite optimization of disease status and 194 
nutrition, although the timing, route of administration, dose of sex steroid and duration of 195 
treatment is unclear. Abnormal bone development is also seen in these adolescents (26-28) 196 
and in these individuals with chronic disease, decisions regarding pubertal induction will also 197 
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need to include careful assessment of bone mass and the potential benefit of sex steroid on 198 
bone acquisition. It is beyond the scope of this current review to address issues of pubertal 199 
induction in chronic disease which we feel is an area of research often neglected. 200 
The availability of recombinant human growth hormone (rhGH) in the past 30 years 201 
has led to its use in non-growth hormone deficient conditions (29) such as Turner Syndrome 202 
(30-32), small for gestational age (33,34), idiopathic short stature (35) , short stature 203 
homeobox (SHOX) deficiency (36), Prader Willi Syndrome (37) and chronic renal 204 
insufficiency (38). In younger pre-pubertal children with chronic disease and in those with 205 
pubertal delay who continue to grow slowly despite pubertal induction, rhGH may be a 206 
therapeutic option. Emerging therapeutic clinical trials of rhGH in pediatric JIA, IBD and CF 207 
suggest that short term linear growth may improve with rhGH therapy. These studies 208 
demonstrate that rhGH, especially at a higher dose, may be able to overcome the relative GH 209 
resistant state seen in chronic disease (39).  210 
The review aims to provide the most up to date summary of growth failure, systemic 211 
abnormalities in the GH/IGF-1 axis and local growth plate disturbances observed in children 212 
with JIA, IBD and CF. In addition, we will summarize and critically evaluate the published 213 
literature on the role of rhGH and rhIGF-1 as growth promoting therapies in these children. 214 
This review is timely given that management of chronic disease has changed 215 
significantly over the last 15 years. Modern therapies have opened up the therapeutic options 216 
of management of these childhood chronic disease but a subset are still non responders to 217 
these treatment and in some instances the occurrence of significant adverse effects preclude 218 
the use of these modern therapies. It is for these reasons that poor growth and abnormalities of 219 
pubertal development may still be encountered and the management of these children and 220 
adolescents can be particularly complex. The full PubMed database was searched with no 221 
time restriction in July 2015 using the following keywords: inflammatory bowel disease, 222 
crohn’s disease, crohn disease, ulcerative colitis, cystic fibrosis, juvenile idiopathic arthritis, 223 
juvenile arthritis, juvenile rheumatoid arthritis in combination with growth hormone, insulin 224 
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like growth factor-1 and IGF-1. Non-English articles were excluded. Relevant articles were 225 
obtained and information synthesized into this literature review by the authors.  226 
 227 
2. Background physiology of normal linear growth 228 
 In this section, we will review the normal regulation of linear growth via systemic 229 
and local factors. The reader is however referred to other recent thorough and excellent 230 
reviews on this area (40-42). It is generally accepted that the GH/IGF-1 axis is a main 231 
regulator of linear growth via its endocrine effects at a systemic level and also via local 232 
autocrine/paracrine mechanisms. Understanding of the systemic and local regulation of 233 
normal linear growth has advanced significantly over recent years. Information on how the 234 
systemic GH/IGF-1 axis interacts with local paracrine factors in the regulation of normal 235 
linear growth is still unknown. Chronic disease via chronic inflammation, glucocorticoid and 236 
poor nutrition can impact growth at multiple levels via their effects on the GH/IGF-1 axis 237 
systemically and at the level of target organ.  238 
 239 
2.1 Systemic regulation of linear growth 240 
The endocrine regulation of normal linear growth involves pituitary derived GH and 241 
the IGF system. It was initially thought that GH itself did not exert its effects directly on 242 
target organs but did so via IGF-1, produced in the liver. It is now known that both GH and 243 
IGF-1 exert separate and independent effects on growth. GH can act to induce the expression 244 
and action of local IGF-1 at the level of the growth plate to lead to increase bone growth (43). 245 
Local injection of GH directly into cartilage growth plates of the hind limbs of 246 
hypophysectomised rats produced significant increase in lengths of the injected limb 247 
compared with the non injected contra lateral limb, pointing to the direct effect of GH on 248 
regulating growth (44). In addition, if all the growth promoting actions of GH are mediated by 249 
IGF-1, then the GH receptor and IGF-1 null mice should be similar to the double GH receptor 250 
and IGF-1 receptor mutant mice (45). Lupu et al showed that post natal mice with combined 251 
GH receptor gene and IGF-1 gene deletion had the smallest size, whereas mice with GH 252 
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receptor gene deletion only were larger in size than those with IGF-I gene deletion (45). 253 
Several other groups also found that body size and tibial growth rate of mice with GH gene 254 
deletion were lower than those with IGF-I gene deletion (46-48). Numerous studies have 255 
produced conflicting results and are unable to pinpoint to the precise mechanism of the action 256 
of GH and IGF-I on the epiphyseal growth plate (49,50).  257 
The relative contribution of hepatic generated IGF-1 to epiphyseal bone growth is 258 
currently unclear (51). In the liver IGF-I deficient (LID) mice, deletion of the liver gene of 259 
IGF-I reduced circulating IGF-I to 25% of the wild type mice. Bone length and body size of 260 
the LID mice were not different from the wild type mice. IGF-I mRNA expression in a 261 
variety of tissues including heart, muscle, fat, spleen and kidney were similar between the 262 
LID mice and the wild type mice, suggesting that there is no compensation from IGF-I 263 
derived from other tissues accounting for the preservation of linear growth in the LID mice 264 
(52). A combined knock out of LID, acid labile subunit knock-out (ALSKO), IGF binding 265 
protein 3 knock-out (BP3KO) had significantly reduced systemic levels of IGF-1 but only a 266 
modest degree of growth retardation, pointing to the possibility of the importance of local 267 
factors regulating bone growth (53).  268 
Mice with targeted deletion of IGF-I in chondrocytes had normal systemic levels of 269 
IGF-I but 40% reduction in local IGF-I.  Body length was however reduced by 27% (54). On 270 
the other hand, elevated systemic levels of IGF-1 were able to rescue the growth impairment 271 
in IGF-1 null mice pointing to the role of systemic IGF-1 on autocrine/paracrine effects (55). 272 
The IGF-1 null mice also have compensatory increase in local IGF-2 locally which may 273 
explain the modest growth impairment in that model. GH promote growth plate 274 
chondrogenesis independent of local IGF-1 and IGF-2 levels (56) and addition of rhIGF-1 to 275 
rhGH treatment in healthy female mice did not lead to improvement in bone growth (57). A 276 
study in a knock in mouse model of mutated IGF-1 with markedly low total IGF-1 and 277 
formation with IGFBPs but high levels of unbound IGF-1 showed significantly increased 278 
body size pointing to the role of free bioavailable IGF-1 on regulation of growth (58)  279 
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It has been suggested that an element of redundancy may exist between local and 280 
endocrine growth factors like IGF-1, where the absence of one source (systemic vs. local) 281 
may be compensated by the other. The regulation of GH and IGF-1 systemically and at local 282 
level may differ in health and in chronic disease (41).  283 
 284 
2.2 Growth plate 285 
The process of bone growth relies upon chondrocytes produced at the epiphyseal 286 
growth plate, which are progressively synthesized and replaced by bone with accompanying 287 
longitudinal (endochondral) bone growth. Growth plate (epiphyseal plate) is a layer of hyaline 288 
cartilage in growing bone located in the metaphysis between the epiphysis and diaphysis. It is 289 
left over cartilage from the endochondral ossification. The epiphyseal plate consists of four 290 
zones (59)  291 
The zone of resting cartilage is near the epiphyses and consists of a small, scattered 292 
chondrocytes. These cells do not function in bone growth therefore; these are termed as 293 
“resting”. Resting zone chondrocytes replicate at a slow rate (60) and act as stem cells that 294 
replenish the pool of proliferative chondrocytes (61).  295 
The zone of proliferating cartilage consists of slightly larger chondrocytes arranged 296 
like stack of coins. Chondrocytes divide to replace those that die at the diaphyseal surface of 297 
the epiphyseal plate. Proliferative zone chondrocytes replicate at a high rate and the cells line 298 
up along the long axis of the bone (60,62) 299 
The zone of hypertrophic cartilage consists of even larger chondrocytes that are also 300 
arranged in columns. The lengthwise expansion of the epiphyseal plate is the result of cell 301 
division in the zone of proliferating cartilage and maturation of the cells in the zone of 302 
hypertrophic cartilage. During the hypertrophic phase, chondrocytes increase their height 303 
about 6-10 fold. Hypertrophic differentiation makes a significant contribution to longitudinal 304 
growth (63). These chondrocytes calcify the surrounding extracellular matrix and produce 305 
factors that attract the invading bone cells and blood vessels (64). Prior to blood vessels 306 
invading the chondrocytes lacuna, they undergo apoptosis (65) 307 
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 308 
2.2.1 Local growth plate regulation 309 
GH acts locally to recruit resting chondrocytes into the proliferative state as well as 310 
stimulate local production of IGF- which in turn stimulates proliferation of proliferative 311 
chondrocytes. Infusion of IGF-1 to hypophysectomized rats stimulate chondrocytes at all the 312 
stages of differentiation, including the hypertrophic zone, clearly pointing to a role of IGF-1 313 
at the local level (66,67).  314 
At a local level, GH action may be regulated by suppressor of cytokine signalling 2 315 
SOCS2) (68). The SOCS2 knockout mice exhibit an overgrowth phenotype associated with 316 
increased GH/IGF-1 signalling leading to wider proliferative and hypertrophic zones of the 317 
growth plate (69). Studies using chondrocytes and metatarsals from the SOCS2 knockout 318 
mice showed increased GH signalling locally and maybe independent of local IGF-1 (70).  319 
The local regulation of growth also involves several other paracrine signalling like 320 
fibroblast growth factors, Indian hedgehog, parathyroid hormone-related protein, bone 321 
morphogenetic proteins and vascular endothelial growth factor (40). How these systems 322 
interact with GH/IGF-1 regulation in health and disease is currently still unknown.  323 
 324 
3.  Inflammation and growth plate abnormalities 325 
3.1 Effects of inflammatory cytokines on the growth plate 326 
Various cell and organ culture approaches have borne evidence demonstrating the 327 
adverse effects of proinflammatory cytokines on growth plate chondrogenesis (71) [Figure 4].  328 
IL-1-β and TNFα decrease both the width of the proliferating zone and the rate of 329 
endochondral bone growth; a possible consequence of altered chondrocyte proliferation, 330 
differentiation and apoptosis rates (71-74). Furthermore, IL-1β and TNFα reduce chondrocyte 331 
expression of cartilage matrix proteins including aggrecan and collagen types-II and -X 332 
(71,75,76). The addition of IL-6 alone appears to have little effect on growth plate 333 
chondrocytes although it may be able to inhibit the early differentiation steps of chondrocyte 334 
precursors (71,73,77-79).  It is possible that IL-6 needs to be added in combination with 335 
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soluble IL-6R to have an effect on chondrocyte proliferation, differentiation and bone growth 336 
(73,80,81). Importantly both IL-1β and TNF-α are also produced locally by growth plate 337 
chondrocytes to regulate physiological bone growth and that the inhibition of endogenous 338 
levels leads to improved longitudinal bone growth (82,83).  The growth and long bone length 339 
of the IL-1 receptor type 1 knock-out mouse were however normal despite a narrower growth 340 
plates due to a smaller hypertrophic zone (84). 341 
The direct analysis of proinflammatory cytokines on linear bone growth has been 342 
aided by the study of cultured fetal metatarsal bones.  IL1-β, IL-6 and TNF-α inhibit linear 343 
growth and in combination they have an additive growth inhibitory effect (71,73,81). 344 
Furthermore, TNF-α and IL1-β also act in synergy to induce IL-6 production in fetal 345 
metatarsals (81). There is also restricted potential for recovery of growth plate chondrogenesis 346 
and longitudinal bone growth following prolonged exposure to pro-inflammatory cytokines 347 
(71) [Figure 5].  This mirrors the clinical impression of greater degree of growth impairment 348 
in those children with longer periods of symptoms prior to diagnosis (85). Addition of 349 
antibodies to TNF-α and IL1-β lead to partial rescue of bone growth in the metatarsal model 350 
(73) [Figure 6a]. 351 
 In addition to analyzing the effects of recombinant cytokines on metatarsal growth, 352 
approaches using biological fluids from children with JIA have also been informative.  These 353 
preliminary studies disclosed that serum from affected children disturbed chondrogenesis and 354 
linear bone growth.  The results with synovial fluid were less consistent, emphasizing the 355 
interindividual variation of the observed effects (86) . As opposed to the partial rescue of bone 356 
growth in metatarsals exposed to cytokines (TNF-α and IL1-β), addition of antibodies to 357 
TNF-α, IL1-β and IL-6 failed to show any improvement in metatarsal growth when exposed 358 
to biological fluid from a child with systemic JIA where a whole range of inflammatory 359 
cytokines may be detected other than TNF-α, IL1-β and IL-6 (86) [Figure 6b]. 360 
Inflammatory cytokines may disrupt growth plate function by inhibiting IGF-1 361 
intracellular signaling (87,88) . Evidence for this is however limited as neither TNF-α, IL-6 362 
nor IL-1β appear to affect IGF-1 receptor expression (71,74,89-91). Alternatively, 363 
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proinflammatory cytokines may disrupt signaling downstream of the IGF-1R.  TNF-α, IL-6 364 
and IL-1β can attenuate IGF-1-induced activation of both the MAPK/ERK 1/2 and the PI-3K 365 
pathways in chondrocytes (74,92). In myoblasts, IL-1β can inhibit the ability of IGF-1 to 366 
phosphorylate tyrosine residues on both of its downstream docking proteins, IRS-1 and IRS- 2 367 
but it is as yet unknown if this also occurs in chondrocytes (87). Proinflammatory cytokines 368 
may also disrupt chondrocyte GH signaling. IL-6 and oncostatin M can activate JAK/STAT 369 
signaling leading to down-regulation of type II collagen, aggrecan core, and link protein 370 
transcription in articular chondrocyte (80,93). Likewise, IL-1β can antagonize GH signaling 371 
through STAT5 in hepatocytes whilst activating STAT3 in mouse kidney tumor cells (94,95). 372 
Whilst the mechanisms by which JAK/STAT signaling is blunted in inflammatory conditions 373 
are unclear, there is an emerging body of evidence implicating a role for the SOCS family of 374 
proteins which can inhibit  JAK2 and STAT activation in a negative feedback loop, and 375 
whose expression is stimulated pro-inflammatory cytokines (96-101). 376 
 377 
 378 
3.2 Effects of glucocorticoid on the growth plate  379 
The growth-suppressing effects of GC appear multifactorial with some GC actions 380 
modifying skeletal responses to the GH/IGF-I axis whereas other evidence indicates a direct 381 
effect of GH on growth plate chondrocytes.  Common to both mechanisms is the interaction 382 
of GC with its cytosolic receptor (GR) which results in the modulation of gene transcription.  383 
This is accomplished via several different mechanisms. First, GCs bind to a cytosolic GC 384 
receptor attached to a heat-shock protein (HSP). The HSP dissociates, and the GR dimerizes 385 
and translocate to the nucleus and binds to promoters on the target gene known as GC 386 
response elements (GRE), resulting in the activation or repression of a specific set of 387 
transcription factors (102,103). It has also been shown that the GR is capable of binding 388 
directly to specific transcription factors such as nuclear factor-κB (NFκB) and activator 389 
protein-1 (AP-1) which are involved in the up-regulation of inflammatory genes. This 390 
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mechanism is ligand-independent and does not require receptor dimerization, therefore 391 
rendering it genetically separable from transcriptional activation (104). 392 
GCs block the activation of the GH-receptor (GHR) and the IGF-1 receptor (IGF-IR) 393 
in chondrocytes, inhibit pulsatile GH release and reduce IGF-1R and GHR expression by 394 
chondrocytes.  GCs also impair IGF-1 signaling, predominantly via the PI3K pathway at the 395 
growth plate (92,105-110). Studies of linear bone growth have shown that dexamethasone 396 
(Dex) and IGF-1 have opposite effects, with Dex decreasing and IGF-1 increasing cell 397 
proliferation.  Furthermore, IGF-1 is able to ameliorate Dex-induced growth impairment 398 
suggesting that IGF-1 may protect the growth plate against the adverse effects of GC (111).   399 
Evidence for a direct effect of GC on the growth plate comes from a study in which 400 
pharmacological levels of local Dex infusion significantly decreased tibial growth compared 401 
with the contralateral limb (112). The GR has since been localized to proliferating and 402 
hypertrophic chondrocytes in the rat (113) as well as hypertrophic chondrocytes in the human 403 
growth plate (114). GC inhibit chondrocyte proliferation and differentiation whilst stimulating 404 
chondrocyte apoptosis and autophagy (105,110,111,115-117). The inhibitory effects of GCs 405 
on chondrocyte proliferation are consistent with GCs disrupting cell cycle progression and 406 
promoting cell cycle exit (118,119). Whilst chondrocyte p21 expression is increased by Dex 407 
this increase does not contribute to GC-induced growth retardation (120,121).The role of 408 
other cyclin dependent kinase inhibitors such as p27 in mediating GC inhibition of 409 
chondrocyte proliferation has also been questioned (122). 410 
GCs may stimulate apoptosis by altering the relative amounts of pro-apoptotic 411 
members of the Bcl-2 family such as Bax and Bid and thereby promote mitochondrial 412 
apoptosis (123,124). The Bax deficient mice display resistance to GC induced growth failure, 413 
confirming that increased apoptosis as a crucial factor in GC induced growth impairment. 414 
(123)The global effects of pharmacological GC doses on chondrocyte gene expression have 415 
been investigated using microarray technologies.  Both down-regulated genes such as secreted 416 
frizzled-related protein and IGF-I, and upregulated genes including serum/GC-regulated 417 
kinase, connective-tissue growth factor and lipocalin 2 have been identified (125,126). 418 
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Novel GCs that have the anti-inflammatory properties of conventional steroids 419 
without one or more of the side-effects have been described (127,128). One of these 420 
compounds AL-438 acts through the GR and whilst retaining full anti-inflammatory efficacy 421 
it has a GC sparing effect on chondrocyte proliferation and longitudinal bone growth 422 
(115,129) . This, and similar compounds, could prove important in the search for new anti-423 
inflammatory treatments for children. GC excess and GH deficiency impair longitudinal bone 424 
growth. After remission, growth often accelerates beyond the normal growth rate for that 425 
particular age, a phenomenon called catch-up growth (130,131). This has also been observed 426 
in many growth-retarding conditions such as Cushing’s syndrome (132), hypothyroidism 427 
(133), celiac disease (134) and anorexia nervosa/malnutrition (132). However catch-up 428 
growth in children with chronic inflammation may not be complete even after discontinuation 429 
of GC treatment if the inflammatory insult is ongoing, which is often the case. 430 
Studies in rabbits in which Dex was infused directly in the tibial growth plate resulted 431 
in slow bone growth of the treated bone but not of the contralateral vehicle-treated bone 432 
(135). After cessation of Dex infusion, tibial bone growth rate was increased compared with 433 
the contralateral leg, thereby demonstrating catch-up growth (136). Based on these findings, 434 
Gafni and Baron (137) proposed that the underlying mechanism for catch-up growth was 435 
intrinsic to the growth plate.  Specifically, the decrease in chondrocyte proliferation noted 436 
during GC treatment conserves the proliferative capacity of chondrocytes and delays 437 
chondrocyte senescence. Therefore, after discontinuation of GC treatment, the growth plate 438 
chondrocytes are less senescent i.e. have greater proliferating potential and thereby explaining 439 
the increased growth rate.  In vitro studies have also shown that Dex-treated cells retain the 440 
capacity to re-enter chondrogenesis following the withdrawal of GC (119). This implies that, 441 
although Dex arrests growth and differentiation of chondrocytes, the capacity for cells to 442 
undergo chondrogenesis is maintained in the presence of GC despite the fact that progenitor 443 
cells are quiescent.  444 
 445 
3.3 Effects of malnutrition on the growth plate 446 
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There is no doubt that undernutrition impairs skeletal growth and contributes to the 447 
growth failure in children with chronic disease. In a rat model of colitis, inflammation itself, 448 
independent of poor nutrition, explains 40% of the growth impairment (138). Aggressive 449 
nutritional therapies are often considered in children with IBD and CF, including the use of 450 
supplemental feeds and gastrostomy feeding. In the last few decades, in CD, the use of 451 
exclusive enteral nutritional (EEN) during acute relapse is generally used in place of oral GC 452 
as first line, except in those with severe disease, in most countries (139).  453 
Rat studies show that undernutrition lead to reduction in GH production  (140) but 454 
also reduction in hepatic GH sensitivity due to decreased GH receptor mRNA in the liver and 455 
resultant low systemic IGF-1 (141,142). In humans, malnutrition is associated with hepatic 456 
GH resistance but associated with elevated systemic GH levels (143,144). Short periods of 457 
fasting (2-3 days) in animal studies report reduction in linear growth by 30% compared with 458 
control animals, associated with reduction in all zones of the growth plate and decrease in 459 
chondrocyte number. In addition, GH receptor and IGF-1 expression is reduced in growth 460 
plates of mice with food restriction (145).  461 
GH resistance during fasting maybe a metabolic adaptation and fibroblast growth 462 
factor 21 (FGF21) has been identified as a key regulating factor inducing gluconeogenesis, 463 
fatty acid oxidation and ketogenesis. Short periods of fasting can lead to elevation of FGF21 464 
(146,147). The link between FGF21 and growth is demonstrated by the fact that transgenic 465 
mice over expressing FGF21 have reduced bone growth and hepatic GH resistance (148). On 466 
the other hand, FGF21 knockout mice subjected to 4 weeks of food restriction did not exhibit 467 
reduction in linear growth and did not show GH resistance (145). Increased FGF21 during 468 
periods of undernutrition affect GH sensitivity by directly inhibiting GH binding in growth 469 
plate chondrocytes with no impact on the number of GH receptors locally. This may be an 470 
indirect effect via the effects of two transmembrane proteins, LEPROT and LEPROTL1, 471 
which are increased during fasting, leading to reduction in GH binding and action at the 472 
growth plate (149). Recently it has been shown that fasting is associated with significant 473 
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increase in microRNA-140 specifically at the level of chondrocytes, although its precise 474 
mechanism on malnutrition growth failure is still unclear (150).  475 
 476 
4. Animal models of chronic disease and growth disorders 477 
Animal models of arthritis and colitis confirm the direct effects of chronic 478 
inflammation on growth, the GH/IGF axis systemically and at a local level. In addition, they 479 
have also provided evidence of the direct role of inflammation on delayed puberty and poor 480 
pubertal growth.  481 
The IL-6 transgenic mice have an adult size that is 50-70% smaller compared to non-482 
transgenic littermates, even after controlling for food intake (151). This was associated with 483 
normal systemic GH but low IGF-1 and low IGFBP-3. ALS levels on the other hand remained 484 
normal (151,152). The low IGF-1 was seen to be due to increased renal clearance whilst the 485 
low IGFBP-3 was due to increased proteolysis (152). Blocking IL-6 reversed the growth 486 
phenotype and normalized IGF-1 levels, pointing to the role of IL-6 on growth failure in 487 
chronic inflammation (153).  488 
In a study of rats with Mycobacterium butyricum induced arthritis, weight gain was 489 
three fold lower than controls. This was associated with low IGF-1 but increased IGFBP-3 490 
due to decrease in proteolysis (154-156). Pituitary GH and liver IGF-1 gene expression were 491 
reduced (157). In a study using a mouse model of systemic arthritis, C-natriuretic peptide 492 
overexpression in chondrocytes prevented endochondral growth retardation and reduced 493 
articular cartilage damage (158). This is thought to be mediated via an increase in 494 
chondrocyte proliferation, differentiation, hypertrophy, matrix production and local resistance 495 
to the effects of pro-inflammatory cytokines (158).  496 
Following trinitrobenzenesulphonic acid (TNBS) induced colitis, rats demonstrate 497 
growth retardation independent of under-nutrition, leading to only 30% of the growth rate of 498 
healthy rats (159,160), associated with normal systemic GH levels but low IGF-1 (159) . The 499 
IL-6 colitis rat also has 30% of the growth rate of controls, associated with low IGF1 levels 500 
(161).  501 
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Studies in TNBS colitis rats and dextran sodium sulphate (DSS) colitis demonstrated 502 
that inflammation causes delayed puberty inconsistent with changes in food intake, body 503 
weight, leptin and corticosterone levels (162-164). Plasma levels of 17β-estradiol in females 504 
and testosterone in male rats with colitis were significantly lower, although basal 505 
gonadotropin levels were similar (162). In females DSS mice with colitis, estradiol and 506 
gonadotropin levels were not lower (164). In males DSS mice with colitis, there was no 507 
difference in testosterone levels but stimulated LH, basal and stimulated FSH levels were 508 
lower in those male mice (163). In our opinion, these animal data suggest that cytokines may 509 
affect the secretion or sensitivity of gonadotropins, or act at the level of the gonadotropin 510 
releasing hormone which may differ depending on gender. Administration of inflammatory 511 
cytokines (165,166) via intracerebroventricular injection and peripheral injection of 512 
lipopolysaccharide (167) have been shown to decrease levels of LH and FSH. Although TNF-513 
α and IL1-β can inhibit steroidogenesis in leydig cells (168), the animal models of colitis do 514 
not support an effect of cytokines on the gonads causing primary gonadal failure as the 515 
etiology of delayed puberty. 516 
CF mice with a null mutation in the CFTR were significantly lighter and shorter 517 
compared with wild type mice associated with significantly lower systemic IGF-1 levels. 518 
Marginal reduction in GH levels were seen only in the female mice (169). CF mice have mild 519 
pancreatic pathology with little or no exocrine pancreatic dysfunction. They however exhibit 520 
growth failure suggesting that pancreatic exocrine status may not play a significant role in 521 
poor growth in this animal model (170). A study in pigs with CF demonstrated growth deficits 522 
at birth with associated lower IGF-1 levels which is due to the lack of CFTR impairing GH 523 
secretion (171).  524 
Adjuvant induced arthritis in rats treated with rhGH showed increased body weight 525 
(156,172) associated with increase levels of  systemic IGF-1 and IGFBP-3 (156,172), with 526 
reduction in IGFBP-1 and IGFBP-2 (156). Also, transgenic mice overexpressing GH with 527 
induced colitis had similar weight trajectory as controls. Compared with wild type mice with 528 
induced colitis, transgenic mice with induced colitis had higher systemic IGF-1 levels (173). 529 
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In contrast, rhGH treatment in interleukin 10-null mice with colitis improved weight gain but 530 
did not raise systemic IGF-1 levels (174). Whilst systemic IGF-1 levels were higher in rhGH 531 
treated rats with colitis, they were still lower than levels in control rats (175). In response to 532 
rhGH therapy, animal models of colitis have reduced hepatic activated tyrosine 533 
phosphorylated STAT5 (176,177). Currently, there are no studies evaluating the growth plate 534 
phenotype in animal models of chronic inflammation treated with rhGH. rhGH in rodent 535 
models may also activate the prolactin receptor. To the best of our knowledge, there are no 536 
animal studies of rhGH in chronic disease specifically targeting the GH receptor. 537 
 538 
 539 
 540 
5. Juvenile idiopathic arthritis (JIA) 541 
5.1 Disease and management 542 
Juvenile idiopathic arthritis comprises a heterogeneous group of disease subtypes 543 
involving inflammatory arthritis’s beginning before the age of 16 years with symptoms 544 
presenting for greater than 6 weeks (178). The pathogenesis is currently unknown although it 545 
is thought to be due to a combination of environmental triggers and specific immunogenic 546 
factors (179,180). There are currently seven subtypes of JIA according to the International 547 
League of Associations for Rheumatology (ILAR) classification (178,181,182). In currently 548 
published literature regarding growth and pubertal development, distinction is generally only 549 
made between those patients with oligoarticular, polyarticular and systemic JIA.  550 
Management of JIA differs depending on the subtype. There is currently no cure for 551 
JIA and treatment is focused on achieving optimal function of joints, preserving or ensuring 552 
normal mobility for day to day activity, ensuring normal growth development and minimizing 553 
negative impact on the child and family (183). Pain relief is achieved with the use of non-554 
steroidal anti-inflammatory drugs (NSAID). 555 
 In those with more severe joint involvement that do not respond to NSAID, intra-556 
articular GC injection is used as second line treatment. Response is usually seen within days 557 
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of injection and a response rate of 60-70% is maintained for several months (184-186). Early 558 
use of intra-articular GC injections, may result in fewer local long term consequences like 559 
contractures, muscle atrophy and leg length discrepancy (187,188). Reports of children 560 
treated with intra-articular GC and development of Cushingoid features exist in the published 561 
literature (189-191). The effect of intra-articular GC injections on linear growth in JIA is 562 
unclear. One study of 21 patients showed no adverse effects on linear growth (192). In a 563 
report of 2 patients with JIA (193), leg growth of the contralateral leg was reduced using 564 
knemometry after intra-articular GC injection. This could reflect local overgrowth of the 565 
affected inflamed limb which can occur in these children (194).  566 
For those with severe arthritis, oral GC may be needed. In some instances, 567 
intravenous GC (methylprednisolone) for a short period may also be required especially 568 
awaiting the therapeutic effects of background immunomodulator(eg methotrexate) (195). 569 
Other aspects of disease management in subtypes of JIA will be summarized in the next sub-570 
sections. 571 
 572 
5.1.1 Oligoarticular JIA 573 
This is the commonest subtype of JIA accounting for almost 50% of all children with 574 
JIA (196). These children have 4 joints or less affected. The arthritis is generally 575 
asymmetrical and predominantly involves the large joints of the lower extremities excluding 576 
the hips. The most commonly affected joints in decreasing order are the knees, ankles, elbows 577 
and the wrists (196,197). A subgroup of patients with oligoarticular JIA have extension of 578 
joint involvement such that there is > 4 inflamed joints after the first six months of disease, 579 
termed extended oligoarticular JIA. Approximately 50% of those who present with ≤ 4 580 
inflamed joints at diagnosis show subsequent extension of involved joints (198,199). It is 581 
unclear if this is a separate entity or if these patients in fact have polyarticular JIA.  582 
 583 
5.1.2  Polyarticular JIA 584 
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This group of children with JIA have 5 or more joints inflamed. All children with 585 
polyarticular JIA generally are likely to require a disease modifying anti-rheumatic drug 586 
(DMARD) such as methotrexate, sulphasalazine or leflunomide; anti-TNF therapy eg 587 
etanercept - or both classes of drugs. It is not uncommon, especially in those with severe 588 
disease, for a short bridging course of oral GC to be used. Current data suggests that 589 
methotrexate is the DMARD of choice in polyarticular JIA with approximately 86% 590 
responders at 2 years (200). Sixty three percent of children with polyarticular JIA will 591 
respond to treatment with methotrexate (201).  592 
In those with recalcitrant disease, anti- (tumor necrosis factor) TNF therapy offers the 593 
possibility of improving inflammation in these children. Etanercept (Enbrel) is the anti-TNF 594 
of choice in JIA. Etanercept is a soluble, dimeric fusion protein consisting of the human p75 595 
TNF receptor fused to the Fc region of the human IgG1. Approximately 74% of children with 596 
methotrexate resistant JIA will respond to treatment with etanercept (202,203). Adalimumab 597 
(Humira), a humanized monoclonal antibody against TNF-α, has also been shown to be 598 
effective in methotrexate resistant polyarticular JIA (204). Several studies have demonstrated 599 
the efficacy of etanercept in improving linear growth in children with JIA,mostly children 600 
with polyarticular JIA (22,205,206). Improvement in growth is greatest in those with lower Ht 601 
SDS at baseline and those not treated with GC. Growth response is modest, with a recent 602 
study from a large group of 191 children demonstrating that change in Ht SDS was only 0.29 603 
SD after two years of therapy (22).  604 
 605 
5.1.3  Systemic JIA 606 
The initial description of children with systemic JIA involves the observation of the 607 
classical triad of remittent fever, typical macular, salmon colored rash and arthritis. The 608 
arthritis could be oligoarticular initially but often progress to polyarthritis with resulting 609 
significant deformity leading to disability. The systemic signs of fever and rash can precede 610 
arthritis up to several months. Growth failure is frequently seen in children with systemic JIA, 611 
especially during acute flare (207). Predictors of poor prognosis in systemic JIA include age 612 
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of onset < 6 years, disease duration > 5 years or persistent systemic features at 6 months of 613 
disease including fever, need for GC and thrombocytosis (208). Whilst anti-TNF therapy is 614 
often used as first line biologic agent in systemic JIA, it is generally less effective compared 615 
to polyarticular JIA. 54% of patients with systemic JIA show poor response to etanercept 616 
(209)  617 
Evidence suggests that systemic JIA is in fact more driven by IL1-β and IL-6 618 
(210,211). Anakinra (Kineret) is a recombinant human (rh) IL-1 receptor antagonist shown to 619 
be effective in several preliminary open label and retrospective studies of children with GC 620 
dependent systemic JIA (211-213). Two recent randomized trials of Anakinra in children with 621 
systemic JIA have documented its efficacy in reduction of inflammation (214,215). Only 622 
about 45% of these children are IL-1 blocker responders and responders are those with lower 623 
number of active inflamed joints, higher absolute neutrophil count (212), suggesting that IL-1 624 
may not be the only driving cytokine in some children with systemic JIA.  625 
In systemic JIA, elevated levels of IL-6 have also been seen and appear to correlate 626 
with arthritis, fever and thrombocytosis (216). Tocilizumab (Actemra) is a humanized 627 
monoclonal antibody against the IL-6 receptor (217) and has been shown to be effective in 628 
early phase III trials of children with systemic JIA despite DMARD and anti TNF therapy 629 
(218). A recent study in a group of children with systemic JIA treated with Tocilizumab 630 
showed that growth rate improve significantly following 2 years of therapy with resultant 631 
normalization of IGF-1. These children however remained relatively short as Ht SDS only 632 
improved by +0.3 SD after 2 years. Ht SDS at baseline was approximately -2.0 SD (219). 633 
 634 
5.2 Clinical evidence of growth failure in JIA 635 
Localized growth impairment is not uncommon even in those with oligoarticular JIA 636 
and may result in significant leg length discrepancy as knees are commonly affected (194). 637 
The temporomandibular joint can also be affected in those with systemic and poly-articular 638 
JIA and may result in relative micrognathia, irregular growth of the jaw (220,221). Recent 3D 639 
facial asymmetry quantification confirms unilateral destruction of cartilage of the mandibular 640 
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condyle (222) in JIA. All these clinical observations point to the role of local bone growth 641 
impairment associated with chronic inflammation.  642 
In JIA, poor growth is more common in children with poly-articular (especially those 643 
with rheumatoid factor positive) and systemic JIA (207,223,224) although approximately 644 
12% of children with oligoarticular JIA have recently been shown to have > 1SD reduction in 645 
Ht SDS at adult height (AH) compared with Ht SDS at diagnosis (225). Evaluation of the 646 
clinically unaffected knee with MRI in a group of children with oligoarticular JIA revealed 647 
abnormalities in 40% (226). It is possible that clinical evaluation may not be sensitive enough 648 
to detect the more widespread joint involvement in some of these children classified as 649 
oligoarticular JIA (227).  Children with very early onset of systemic JIA (≤ 18 months) have a 650 
more severe disease phenotype and unsurprisingly poor growth is more frequent (228). 651 
Onset of puberty maybe delayed in JIA by about 0.4 to 2.2 years compared to healthy 652 
children (229,230). Progression through puberty can be compromised in JIA. None of the 653 
adolescents with JIA reached breast and genital stage 5 at 16 years despite the onset of 654 
puberty between 12-13 years in one study (230). A few studies have reported that onset of 655 
puberty may be earlier in children with systemic JIA in comparison with the other subtypes of 656 
JIA (229,231). These preliminary data need to be interpreted with care as the onset of puberty 657 
was defined by genitalia stage from patient self-assessment rather than clinical examination of 658 
testicular volume. Menarche in girls with JIA is delayed by one year compared to healthy 659 
girls and also to maternal age of menarche. Age of menarche was significantly later in those 660 
with systemic JIA in this study (232). Other studies found no difference for age at menarche 661 
for girls with JIA (233,234). 662 
Pubertal growth spurt in JIA may be attenuated and is often poorest in those with 663 
systemic JIA (231). In one study, actual HVs for children with oligoarticular and polyarticular 664 
JIA were approximately 1.5 cm/ year for those children aged 12-16 years whilst HV was only 665 
approximately 0.5 cm/ year for those with systemic JIA. A substantially compromised 666 
magnitude of peak height velocity (2.8 cm/year) was reported in this study. Peak height 667 
velocity was 3.6 cm/year for oligo-articular JIA, 4.9 cm/year for polyarticular JIA and 1.7 668 
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cm/year for systemic JIA (231).  HV for healthy children in puberty ranges from about 4-8 669 
cm/year on average.  670 
Current published studies report significant reduction in adult height (AH) in JIA 671 
(198,207,235-239) [Table 1]. However, these studies were published over a decade ago which 672 
would have included children treated in the 1980s. The use of immunomodulators and anti-673 
cytokine have only been incorporated into routine clinical practice in the last 10-15 years. 674 
Current studies of AH in JIA include different numbers of the various subtypes of JIA. The 675 
study by Simon et al from 2002 which reported a mean AH of -2.0 SD only included children 676 
with systemic JIA who were treated for approximately 7 years with continuous oral GC, a 677 
practice that is less common these days even in children with severe systemic JIA (207). AH 678 
of individuals with JIA treated with contemporary immunomodulators and anti-cytokine 679 
therapy is currently unknown. In addition, there is increasing use of intra-articular injection of 680 
GC instead of prolonged use of oral GC which may be beneficial for controlling joint 681 
inflammation but has less systemic side effects. It is possible that there may be growth 682 
suppressive effects of intra-articular GC especially for those children who require multiple 683 
repeated injections.  684 
Growth and pubertal development in other less common inflammatory rheumatologic 685 
conditions such as systemic lupus erythromatosus (SLE), dermatomyositis, and systemic 686 
sclerosis are not well studied. In a 2 year follow up study of 331 children with SLE, short 687 
stature was uncommon at baseline of study visit (median Ht SDS -0.4, median parent adjusted 688 
Ht SDS -0.3). However, Ht SDS continued to deteriorate despite institution of therapy, 689 
particularly pronounced in boys. Parents adjusted Ht SDS < -1.5 was seen in 25% and 15% of 690 
males and females at end of study, respectively (240). In SLE, delayed onset of puberty was 691 
seen in 15.3% of girls (breast stage 2) and 24% of boys (testes ≥ 4ml). Over twenty per cent 692 
of adolescent girls with SLE had delayed menarche (>15 years) or absent menarche. Irregular 693 
menses and secondary amenorrhea was seen in fewer than fifty per cent.  In the group of older 694 
adolescent girls, delay onset of puberty, pubertal tempo or menarche was seen in over one 695 
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third of girls whereas in older boys, delay onset of puberty and pubertal tempo was seen in 696 
almost fifty per cent (241).  697 
Some studies have reported an association between GC and growth failure in JIA  698 
(236,242) whilst others have not (227,237,243). One study evaluated the relationship between 699 
inflammatory cytokines and linear growth in 79 children JIA.  HV Z score was associated 700 
with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and IL-6. IL-6 was the 701 
only significant factor (independent of other disease markers and GC dose) influencing 702 
growth rate on regression analysis in this study, highlighting once again the importance of 703 
disease itself on growth failure (244).  Although it is often difficult to separate the impact of 704 
GC and inflammation on growth impairment, judicious use of oral GC may have less impact 705 
on growth than uncontrolled inflammatory status. However, undoubtedly, prolonged high 706 
dose of systemic GC will have a negative effect on growth.  707 
To summarize this section, significant growth impairment leading to short stature is 708 
often seen in children with severe poly-articular JIA and systemic JIA. The recent report of 709 
long term growth problems in children with oligo-articular JIA needs to be confirmed in 710 
further studies. The extent of long term growth failure and short stature at AH in a cohort of 711 
individuals with JIA managed with modern therapies is currently unknown.  712 
 713 
5.3 Systemic abnormalities in GH/IGF-1 axis in JIA 714 
Chronic inflammation in JIA is associated with a state of relative GH resistance. A 715 
biochemical picture of GH resistance was seen in six slowly growing children with systemic 716 
JIA who had normal GH secretion from overnight GH sampling, normal GH response to two 717 
provocative tests (clonidine and ITT) but low IGF-1 and IGFBP-3  levels (245). Nine out of 718 
ten children with JIA underwent overnight GH sampling had normal GH secretion (246). 719 
Following 4 days treatment with rhGH (0.23 mg/kg/wk), IGF-1 and IGFBP-3 only increased 720 
by 31% and 14% respectively in JIA, whilst IGF-1 and IGFBP-3 rose by 85% and 73% in 8 721 
children with constitutional delay in puberty (247). The resistance to GH in JIA is due to a 722 
reduction in GH receptor gene expression. Following a 2 year follow up period, GH receptor 723 
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mRNA in lymphocytes of JIA increased, paralleled by improvement in disease activity, 724 
reduction in IL-6 levels and increase in IGF-1 levels (248)  725 
Impairment of GH secretion is also seen in children with JIA. Twenty three out of 63 726 
children with JIA who had been treated with GC for a mean of approximately 4 years at mean 727 
0.2 mg/kg/day Prednisolone at evaluation had evidence of GH deficiency by clonidine and/or 728 
arginine stimulation test (249). In a group of children with JIA not on oral GC, abnormal GH 729 
secretion was diagnosed in 50% based on results of overnight GH sampling and L-Dopa 730 
stimulation test, suggesting that inflammation itself may also impair GH secretion. The cut off 731 
for GH sufficiency was taken at the level equivalent to 10 mcg/L (250). The recommended 732 
peak GH of < 10 mcg/L has not been validated and this arbitrary cut off may need to be 733 
altered with the availability of newer monoclonal GH assays (251,252). These may vary 734 
depending on the provocative agent used. However, the clinical studies in JIA mirrors results 735 
experimental studies in animal models of chronic inflammation induced by 736 
lipopolysaccharide and endotoxin demonstrating that pituitary derived GH production can be 737 
reduced (154,253). The impact of intra-articular GC injections on GH secretion in children 738 
with JIA is unknown.  739 
Impairment of IGF binding proteins have also been reported in children with JIA. In 740 
26 children with systemic JIA, normal levels of ALS, low IGF-1 and markedly low IGFBP-3 741 
due to increase proteolysis of IGFBP-3 were reported (152).  In another study of 17 children 742 
with JIA (majority olio-articular JIA) and mild growth failure, normal IGF-1, marginally low 743 
IGFBP-3 but disproportionately low ALS was reported (254).  744 
Whilst low levels of IGF-1 are generally seen in most studies of childhood arthritis, 745 
some studies suggest that poorly growing children with inflammatory rheumatic conditions 746 
may have IGF-1 in the normal ranges, which suggest that a functional state of relative IGF-1 747 
resistance may exist (246,255,256). In 23 children with JIA, mean IGF-1 SDS adjusted for 748 
age was -0.84. Five of those individuals had relatively “high” IGF-1 SDS > +1 SD (216). It is 749 
possible GC treatment in the presence of inflammation reduces IGF-1 sensitivity.  A study of 750 
32 adults with rheumatoid arthritis (16 on Prednisolone) showed that IGF-1 was significantly 751 
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higher in the group on Prednisolone (mean 221 microgram/L vs. 122 microgram/L). Twelve 752 
weeks treatment with anti-TNF therapy (adalimumab) led to normalization of the raised IGF-753 
1 in the group on Prednisolone such that the levels were similar in both groups. (256).  754 
To summarize this section, studies of the systemic GH-IGF axis in children with JIA 755 
point to a state of GH resistance in the majority of the cases. Abnormalities in GH secretion 756 
may also exist in non-GC treated children, although this could be due to the impact of intra-757 
articular GC. Abnormalities of IGF binding proteins are reported in children with JIA but 758 
comprehensive studies of the ternary complex are still currently unavailable. IGF-1 resistance 759 
especially in those treated with high dose GC may also occur. Whilst GH/IGF-1 resistance 760 
occurs in JIA, there is insufficient scientific evidence to determine the contribution of 761 
systemic hormone resistance on growth impairment in children with JIA. 762 
 763 
5.4 Efficacy of rhGH on linear growth in JIA 764 
Earlier non-randomized studies that included children with JIA who were relatively 765 
older reported that HV can improve by over 100% with rhGH (247,257-264) [Table 2]. 766 
Subsequent randomized controlled trials including one with a placebo arm have confirmed 767 
these findings and suggest a modest effect on short to medium term catch-up growth [Table 3] 768 
(39,250,265-268) 769 
Two studies that compared different doses of rhGH suggested better growth response 770 
with the “higher” dose compared with the “lower dose” (0.16 mg/kg/wk vs. 0.33 mg/kg/wk 771 
and 0.15 mg/kg/wk vs. 0.30 mg/kg/wk) (247,260).  A recent trial in JIA has investigated even 772 
higher doses of rhGH (0.47mg/kg/week) (268). The growth response appears to be better in 773 
this study but the subjects in this trial had shorter duration of disease and GC exposure.  774 
The only randomized study with AH data in chronic inflammatory disease was 775 
conducted as an RCT using rhGH 0.33 mg/kg/wk for a mean duration of 8.4 years and it 776 
reported a mean difference of 14.3 cm at AH between the two groups. Treatment led to a net 777 
gain of Ht SDS of +2.3 SD as the control group lost 0.7 SD from baseline to AH. At AH, 778 
rhGH treated patients were still relatively short with mean AH of -1.6 SDS. However, 779 
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untreated children had a mean AH of -3.4 SDS (39) [Fig 8]. The efficacy of rhGH on AH in 780 
JIA is similar to gains seen in children with chronic renal insufficiency (CRI) treated with 781 
rhGH (269,270).  782 
In a non-randomized study using rhGH 0.33 mg/kg/week, using data from some of 783 
the children previously included in a randomized trial and patients clinically treated with 784 
rhGH off label, mean total pubertal height gain was 7.3 cm better with rhGH treatment.  785 
Similarly, mean AH in the rhGH group was – 1.7 SD whilst the AH of the matched controls 786 
was -3.2 SD (249). Total pubertal growth with rhGH in JIA is comparable to children with 787 
idiopathic GH deficiency treated with rhGH and healthy children during puberty 788 
(249,271,272). 789 
To evaluate the role of “early” use of rhGH before significant short stature is present, 790 
Simon et al conducted an RCT using rhGH 0.47 mg/kg/wk in a group of prepubertal children 791 
with JIA who were growing at less than 3cm/year and had a mean Ht SDS of about -1.0. 792 
These children had a relatively short duration of disease of approximately 2 years at baseline. 793 
After 3 years of rhGH, the relative Ht gain was +1.5 SD (268). These data suggest that early 794 
introduction of rhGH in the course of JIA before the onset of severe growth impairment may 795 
normalize growth rate. The benefit of “early” treatment with rhGH before the onset of severe 796 
growth failure needs further evaluation particularly in light of newer therapeutic development 797 
in JIA disease management, although we know that catch-up growth following anti-cytokine 798 
therapy may only be modest (22). 799 
There is now sufficient evidence to show that the use of relatively high dose rhGH 800 
leads to improvement of linear growth in children with JIA. Only one study with information 801 
on AH using rhGH dose similar to those used in conditions like TS and CRI report fairly 802 
similar AH outcome. Larger, adequately powered trials of rhGH in JIA are now needed to 803 
confirm long term AH outcome and address issues like optimal dose of rhGH and timing of 804 
starting rhGH. The impact of rhGH in those with systemic JIA, often the ones most severely 805 
affected, is still unclear, as current trials have included only a small number of such children. 806 
Future rhGH studies will also need to stratify for JIA subtypes at inclusion.  807 
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 808 
5.5 Factors affecting the growth response to rhGH in JIA 809 
5.5.1 Disease status and glucocorticoid 810 
Studies of rhGH in JIA have demonstrated that the growth response to rhGH is 811 
negatively associated with inflammatory markers such as CRP (39,260) and ESR (39). Some 812 
studies also found a negative association between cumulative prednisolone dose and growth 813 
rate during rhGH therapy (255,261,265,266). The association between prednisolone dose and 814 
growth rate was not statistically significant when the analysis was performed in a regression 815 
model, suggesting that inflammation plays a greater role in modulating growth response (39). 816 
One study showed that children with polyarticular JIA grew better on rhGH than those with 817 
systemic JIA although the number of children with systemic JIA was relatively small (263) 818 
 819 
5.5.2 Systemic IGF-1 levels 820 
A modest positive association has been reported between growth rate with IGF-1 and 821 
IGFBP-3 in response to rhGH. AH of the rhGH and control patients in the study by Bechtold 822 
et al showed a modest association with average IGF-1 and IGFBP-3 in JIA (r= 0.61 for IGF-1 823 
and IGFBP-3) over the treatment period (39).  824 
 825 
5.6 Efficacy of rhGH on disease process in JIA 826 
There are no published studies of rhGH on its effects on experimental arthritis, but 827 
there is currently no evidence to suggest any specific concerns about worsening of 828 
inflammatory arthritis. 829 
 830 
 831 
6. Inflammatory bowel disease (IBD) 832 
6.1 Disease and management 833 
Inflammatory bowel disease is a group of inflammatory disorders of the 834 
gastrointestinal tract characterized by chronic inflammation. IBD has a relapsing and 835 
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remitting nature, which is often unpredictable. IBD has classically been categorized into 836 
ulcerative colitis (UC) and Crohn’s disease (CD) on the basis of combinations of clinical 837 
presentation, radiological and endoscopic and histopathological features. Recent evidence 838 
suggests that the underlying etiology of IBD is due to the interaction of three factors: genetic 839 
susceptibility, environment abnormal immune host response and commensal gut microbiota 840 
(273). It is believed that the pathogenesis of IBD occurs from errors in the interpretation or 841 
regulation of immune perception and responsiveness to endogenous microbiota and thus 842 
disruption in mucosal homeostasis. This results in the initiation of immune responses in 843 
genetically predisposed individuals (274). Familial aggregation of IBD has long been 844 
recognized (275-278), but in the last twenty years detailed mapping of a region on 845 
chromosome 16 resulted in the identification of the NOD2/CARD15 gene. This gene encodes 846 
a cytoplasmic protein designated NOD2 or CARD15, which serves as a pattern recognition 847 
receptor for bacterial lipopolysaccharide and regulates activation of nuclear factor-kβ and 848 
secretion of a-defensins by ileal paneth cells (279-281). Numerous other candidate genes have 849 
subsequently been identified but only accounts for a small proportion of pediatric IBD (282-850 
284).  851 
Focusing specifically on growth and genetic influences in pediatric IBD, studies have 852 
shown that patients with an OCTN1/2 haplotype (285) and those with the IL6-174 GG 853 
genotype had lower height at diagnosis (161).  Another study revealed that patients with TNF-854 
α promoter polymorphism had higher Ht SDS at diagnosis (286). A much more recent study 855 
reported significant association between growth impairment in CD and a stature related 856 
polymorphism in the dymeclin gene (287). To date, it is unclear if these associations with 857 
genetic factors are independent of the severity of inflammation 858 
6.1.1 Ulcerative colitis 859 
UC is a condition where the inflammatory response and morphologic changes remain 860 
confined to the large intestine, with rectal involvement in about 95% of cases. In UC, 861 
inflammation is limited to the mucosa and consists of continuous involvement of variable 862 
severity, with ulceration, edema and hemorrhage along the length of the colon. Characteristic 863 
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histopathological findings are chronic mucosal inflammation with extensive polymorph 864 
nuclear leukocytes, mononuclear cells, crypt abscesses, and distortion of mucosal goblet 865 
glands and goblet cells. Induction of remission at diagnosis and subsequent acute relapse is 866 
with oral GC. Maintenance of remission in UC is with background therapies like amino 867 
salicylates (mild disease) or immunomodulators (eg azathioprine, methotrexate) and anti-868 
cytokine disease. In UC, major surgery with total colectomy and ileal pouch anal anastomosis 869 
is curative (288). The efficacy of anti-cytokine therapy in UC is unclear and as such not used 870 
as frequently (289).  871 
 872 
6.1.2 Crohn’s disease 873 
In contrast, CD is inflammation that can involve any part of the gastrointestinal tract 874 
from the oropharynx to the perianal area. Diseased and inflamed segments are separated by 875 
normal healthy bowel otherwise known as “skip lesions”. Inflammation can be transmural, 876 
often extending to the serosa, resulting in sinus tracts or fistula formation. Typical 877 
histopathological findings include small superficial ulcerations over a Peyer’s patch and focal 878 
chronic inflammation extending to the submucosa and sometimes accompanied by non 879 
caseating granuloma formation. Common sites involved are the ileocecal region, terminal 880 
ileum, small bowel and isolated colonic involvement.  881 
In CD, induction of remission of mild to moderate disease is often with exclusive 882 
enteral nutrition (EEN) (290). This is the provision of an exclusive liquid diet for a duration 883 
of 8-12 weeks which has been shown to be just as effective as GC for reduction of 884 
inflammation and but has no adverse effects on growth and bone metabolism (291). EEN is 885 
commonly used in Europe and is gaining popularity in the United States and the rest of the 886 
world. Background maintenance therapy using amino salicylates or immunomodulators with 887 
azathioprine are often used in moderate to severe disease close to the time of diagnosis. 888 
Methotrexate can be used as a second line immunomodulatory (292). 889 
 Escalation to anti-cytokine therapy like infliximab and adalimumab will be 890 
considered in those children with severe disease who are not responsive to GC and those with 891 
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chronic low grade inflammation but who are GC dependent. In the real world setting, the use 892 
of anti-TNF therapy in paediatric CD is associated with modest response with 56% achieving 893 
remission after 12 months (293). Safety issues like significant acute reactions and long term 894 
safety concerns including lethal forms of lymphoma preclude its use over extended periods of 895 
time (294,295). There is no doubt that the use of anti-TNF therapy in CD is associated with 896 
improvement in linear growth (296-298). Similar to the experience in children with JIA, this 897 
improvement is only modest with studies reporting increased in Ht SDS of between 0.2 to 0.3 898 
SD over 12 months of therapy (299).  899 
 900 
6.1.3 Inflammatory bowel disease unclassified 901 
CD involving the colon only is commoner is children than in adults which makes it 902 
challenging to distinguish CD and UC for some individuals. In these instances, the term IBD 903 
unspecified (IBDU) is used (previously known as indeterminate colitis). Observational studies 904 
suggest that children with IBDU could be considered a distinct subtype of IBD as the disease 905 
often takes an aggressive and progressive course (300)(REF).  906 
 907 
6.2 Growth failure in children with IBD 908 
In IBD, growth impairment appears to be more frequent and severe in children with 909 
CD than those with UC (18,301,302).(303,304) A UK IBD register that collected data for new 910 
cases presenting between 1997 and 2003, reported that, at diagnosis, mean Ht SDS was -0.3 911 
for both boys and girls with CD whereas it was -0.1 and +0.22 for boys and girls with UC, 912 
respectively (305). Ht SDS < -2.0 is present in approximately 10% of children with CD at 913 
diagnosis (18,306,307). In another recent study, mean Ht SDS for 102 children with CD 914 
(mean age 11.9 years) was -0.2, but those with Saccharomyces cerevisiae antibody (ASCA) 915 
had significantly lower height that those without (308). Whilst height reduction at diagnosis 916 
as a group appears to be mild, deteriorating height velocity is known to occur before the 917 
diagnosis of CD and can occur in the absence of gastrointestinal symptoms (309). A 918 
retrospective study of 116 children with CD provided further evidence for this as these 919 
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children were shorter than their genetic potential at diagnosis with mean Ht SDS of -0.5 920 
compared with mid-parental Ht SDS +0.2 (18).  921 
Several contemporary studies show that despite modern therapies, growth failure and 922 
short stature is still seen in a subset of children and adolescents with IBD (18,307,310). A 923 
study in a cohort of contemporary children and adolescents with IBD showed that Ht SDS 924 
showed a negative association with the body image domain of the pediatric IBD specific 925 
quality of life score IMPACT III, with higher scores indicating poorer quality of life (10) [Fig 926 
8]. Further research on the impact of abnormal growth and pubertal development and the 927 
impact on quality of life in children with IBD and other groups of chronic disease are needed. 928 
This is a challenging area to acquire meaningful information as there needs to be distinction 929 
between the impact of poor growth and the impact of the disease itself on quality of life.   930 
Delayed onset of puberty has been previously reported to be common in CD (6,311-931 
313), although careful evaluation of pubertal status by clinician examination is currently 932 
limited (10,311). Other current published studies have used age of menarche, bone age delay 933 
and age at initiation of growth spurt as assessment of pubertal delay (6,312-314). A report 934 
from the mid-90s showed that onset of breast development was delayed by 1.5 years in 935 
children with CD and UC. Boys in that study had 0.8 years delay in onset of testicular 936 
enlargement consistent with early puberty. This report is from a time when 937 
immunomodulators and certainly biologic therapy would not been used in clinical practice 938 
with heavy reliance on long term oral GC therapy.  939 
Although the treatment of children with IBD has changed considerably, a study from 940 
a contemporary cohort of children who analyzed retrospective pubertal growth data reported 941 
persisting evidence of delayed puberty as judged by the age at peak height velocity in those 942 
with CD. This delay was more likely in those with a higher ESR or lower BMI. Peak HV SDS 943 
adjusted for pubertal age was also reduced, suggesting that the pubertal growth spurt may be 944 
attenuated.  This study however, excluded children who were treated clinically with growth 945 
promoting therapy like sex steroid and / or rhGH, who by default are likely to be those with 946 
significant short stature or severe growth retardation (6). Therefore it is possible that there is 947 
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greater impact on puberty and pubertal growth spurt despite modern therapy. A recent 948 
prospective study of a cohort of children and adolescents with IBD suggests that pubertal 949 
delay was uncommon with only 0.3 years of bone age delay. Adolescent boys had attenuated 950 
growth rate during puberty whereas marginally delayed onset of puberty was seen in 951 
adolescent girls with IBD in this contemporary cohort (10). 952 
Two studies demonstrated bone age delay of approximately one year in children with 953 
CD (312,313,315), which is within acceptable limits, including one study from patients 954 
managed between 2007-2009 with 60% of patients on immunomodulators and 20% on 955 
infliximab (315) In girls, age at menarche occurred after 16 years in 73% with CD in a cohort 956 
managed between 1968 and 1983 (314).  In a cohort managed between 2007-2009, girls with 957 
CD reached menarche at median age of 13.9 years (313)compared with healthy controls of 12 958 
years.  959 
Several contemporary studies of growth in children with IBD show lack of adequate 960 
catch up growth despite advances in primary disease therapy. In a study of 176 children with 961 
CD, Ht SDS at diagnosis, 1 and 2 years remain unchanged at approximately -0.5 SD. The 962 
percentage of children with Ht SDS < -2.0 however was slightly less frequent by 2 years: 10% 963 
at diagnosis, 8% 1 year, 6.5% 2 year. This cohort was largely managed with oral GC 964 
(Prednisolone) for induction of remission as only 4% had primary enteral nutrition therapy 965 
within 3 months of diagnosis. (306). Another study of 116 children with CD where enteral 966 
nutrition was more commonly used for induction of remission (63% of cases from diagnosis), 967 
Ht SDS (approximately -0.5 SD) remained the same from diagnosis to a mean final follow-up 968 
of 4.6 years after diagnosis (18).  969 
In contrast to JIA, only a modest reduction in AH has been reported by most studies 970 
in adults with childhood-onset IBD (3,8,9,303,314,316-319) [Table 4]. AH is significantly 971 
lower in childhood onset CD with onset before puberty, although definition of puberty in this 972 
study was unclear (320). In a relatively contemporary cohort of 123 patients with CD,  AH 973 
was only 2.4 cm lower than target height. However almost twenty per cent achieved a AH that 974 
was more than 8cm below their mid-parental height suggesting that a small sub-group of 975 
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adults with childhood onset CD may have significant long term growth impairment leading to 976 
short stature. Longer duration of symptoms prior to diagnosis and jejunal disease were related 977 
to AH in that study but these factors require further study (9). Conventional assessments with 978 
endoscopy and barium studies often do not identify jejunal disease adequately, questioning 979 
the relationship with AH in that study. Parents’ heights were also obtained from patient 980 
estimation. In another study of AH in IBD where 108 patients had AH and parental height 981 
measurements performed by researchers, 28 out of 108 (26%) who had more than one Ht SDS 982 
< -1.6 during growth (defined as growth impaired group) had AH of 0.9 SD lower than mid-983 
parental Ht SDS. In those with no evidence of growth impairment, defined as those who did 984 
not have Ht SDS < -1.6 more than once during growth, AH was only 0.1 SD lower than mid-985 
parental Ht SDS. (319).  986 
Published evidence suggests that short term linear growth may be better in those 987 
children managed with enteral nutrition during acute relapse compared with oral GC 988 
(321,322), although the effects of EEN practice on long term growth outcome is less 989 
convincing. AH in CD (-0.4 SD) did not differ between an American study (319) and a United 990 
Kingdom study (-0.3 SD) (9) where the agent of induction of remission differed: oral GC in 991 
the American study and EEN in the United Kingdom study. Similarly, in a group of children 992 
with CD managed with EEN at initial diagnosis and who were encouraged to continue to take 993 
supplemental enteral nutrition, weight and BMI SDS increased up to 2 years follow-up, 994 
whereas Ht SDS remained unchanged (323).  995 
Numerous studies of anti-cytokine therapy using infliximab and adalimumab in CD 996 
show significant improvement in growth rate (296-298), although some did not demonstrate 997 
any improvement in linear growth (324,325). The improvement in growth in these children 998 
may be independent of progression in puberty, reduction in GC, and maybe better in those 999 
who are concurrently treated with methotrexate. However approximately 30% of these 1000 
children may still have poor growth following biologic therapy (296).  1001 
Clinical studies in children with IBD have largely shown no relationship between GC 1002 
and linear growth (304,326). Saha et al, reported no difference in Ht and HV SDS in 1003 
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prepubertal children with CD and UC treated with GC versus those who did not receive GC. 1004 
(243). A more recent study of a cohort of 102 children with CD treated with long term low 1005 
dose oral GC in the form of Prednisolone (mean dose of 0.2 mg/kg/day for mean 14.4 1006 
months) showed that almost twenty per cent of the cohort showed growth failure, although 1007 
HV was not adjusted for delayed puberty. Of those with growth failure, only one third showed 1008 
catch up growth after discontinuation of GC (327).   1009 
Several studies have evaluated the association between cytokines with linear growth 1010 
and markers of the GH-IGF axis in children with IBD. In 37 children with IBD (17 CD), IGF-1011 
1 levels were lower whilst IGFBP-2 was higher compared with controls during relapse. IL1-β 1012 
levels were related to negatively with IGF-1 and positively with IGFBP-2 (328). Levels of 1013 
lipopolysaccharide was significantly higher in children with CD lower height at diagnosis and 1014 
follow-up (329).Several studies of genetic polymorphism in genes regulating cytokine 1015 
production have shown a relationship with growth impairment in pediatric IBD. Children with 1016 
CD with the -174 GG promoter polymorphism which affects IL-6 transcription had 1017 
significantly lower Ht SDS at diagnosis (161). The presence of 238G/A and 863C/A 1018 
polymorphism on the TNF-α promoter gene has been shown to be associated with better 1019 
height and linear growth in children with CD and appears to be independent of disease 1020 
activity (286). 1021 
Current studies suggest that a sub-group of children with IBD especially those with 1022 
CD have significant growth failure leading to short stature at AH. Despite the introduction of 1023 
modern GC sparing therapies including anti-cytokine therapies, poor growth is still 1024 
encountered, although significantly delay in onset of puberty is perhaps less common. The 1025 
authors believe that the persistence of poor growth in a small group of these children reflect 1026 
the fact that some children with CD still do not achieve disease remission with current 1027 
therapies or adverse effects preclude the use of aggressive modern therapies. Given the short 1028 
window for growth in CD, as the age of presentation is often in the adolescent years, adjuvant 1029 
growth promoting therapies may still need to be explored in this small subset. Finally, the 1030 
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growth outcome of children with IBDU who may have a more severe disease course is still 1031 
currently unclear.  1032 
 1033 
6.3 Systemic abnormalities in the GH/IGF-1 axis in children with IBD 1034 
Similar to children with JIA, growth failure in IBD is associated with a state of GH 1035 
resistance. Early evaluation of the GH axis in 10 children with IBD showed excessive rather 1036 
than impaired response, using overnight GH profile, propranolol-glucagon and ITT, 1037 
supporting the notion that these children may be GH resistant (330). IGF-1 levels have been 1038 
shown to be low in these children, although again delayed maturation may contribute to these 1039 
result (331).  Similarly, in 14 children with CD and growth failure who were not on oral GC, 1040 
normal GH response to ITT was seen in most of the children. Four out of 14 (29%) of these 1041 
children  had peak GH levels < 6 mcg/L suggesting abnormalities in GH secretion (332). In a 1042 
study of 5 children with CD with poor growth and delayed puberty (median age 15 years, 1043 
median bone age 11 years and all except one patient was in Tanner I and II), three out of the 5 1044 
had inadequate five hour mean GH levels and peak GH during sleep-further evidence that 1045 
subtle abnormalities in GH secretion may exist. However, only one child had low GH peak to 1046 
ITT and none of these 5 children were on oral GC (333).  1047 
Abnormalities in the GH axis may be present at diagnosis of children with IBD (330). 1048 
In addition, abnormalities in the GH-IGF axis in children with chronic inflammation are not 1049 
permanent as they have been shown to be responsive to primary disease therapeutic 1050 
intervention using Prednisolone (334), enteral nutrition (335,336), infliximab (337) and 1051 
surgical resection (336).  1052 
It is now recognized that a range of abnormalities in GH and IGF-1 secretion and 1053 
sensitivity exists in children with IBD and growth failure (338) [Fig 9]. In 28 children with 1054 
IBD (25 CD) evaluated with an ITT, 11 (39%) had peak GH > 6 mcg/L and IGF-1 SDS < 0 1055 
(biochemical functional GH resistance). Biochemical functional GH deficiency defined as 1056 
peak GH < 3 mcg/L and IGF-1 SDS < 0 was seen in 4 (14%). Biochemical functional GH 1057 
insufficiency defined as peak GH < 6 mcg/L but ≥ 3 mcg/L and IGF-1 SDS < 0 was seen in 1058 
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11 (39%). Two children had normal GH levels and IGF-1 SDS ≥ 0 suggestive of biochemical 1059 
functional IGF-1 resistance. 1060 
Comprehensive studies of the IGF binding protein and ternary complex in children 1061 
with IBD are currently not available. In a contemporary group of children and adolescents 1062 
with IBD, pubertal onset was not delayed but abnormal pubertal growth was observed. This 1063 
was associated with reduction in IGF-1 levels but marginally elevated IGFBP-3, which was 1064 
postulated to lead to reduction in bioavailability of free IGF-1 (10). A recent study reported 1065 
gender differences in IGF-1 and IGFBP-3 levels in children with CD such that boys had 1066 
significantly lower levels even after adjusting for bone age delay, although Ht SDS was 1067 
similar in both groups (315). A previous study suggested that females with CD had a more 1068 
severe disease course, although males were more likely to exhibit growth failure (339).  One 1069 
study previously reported that IGFBP-2 is significantly higher in children with CD at relapse 1070 
and that this was associated with IL-6 (328). The role of IGFBP-2 and regulation of linear 1071 
growth is unclear but it is thought that it may lead to reduction of the formation of ternary 1072 
complex and may have a direct inhibitory role at the level of the growth plate (340,341). 1073 
In summary, growth failure in children with IBD is associated with a range in defects 1074 
in secretion and sensitivity of the GH-IGF1 axis. The relative contribution of inflammation, 1075 
use of GC and nutrition on these systemic abnormalities is difficult to tease out from current 1076 
studies. Indeed, the contribution of these systemic abnormalities on the growth phenotype of 1077 
these children is unclear. Studies with comprehensive evaluation of IGF binding proteins are 1078 
limited in children with IBD. IGFBP-2 may be a marker of disease in children with IBD but 1079 
whether IGFBP-2 plays an inhibitory role on linear growth in childhood IBD is still unknown.  1080 
 1081 
6.4 Efficacy of rhGH on linear growth in IBD 1082 
Compared to studies in JIA, there is a paucity of data of rhGH in children with IBD 1083 
[Table 5 (342-348) and Table 6 (349-351)]. A non-randomized study of rhGH (0.35 1084 
mg/kg/wk) in 10 children  (Mean age 11.9 yrs, Ht SDS of -1.8) reported an 85% increase in 1085 
HV at 6 months rising from 4.0 cm/yr. to 7.4 cm/yr. This improvement was maintained in a 1086 
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subgroup of seven children who continued treatment for a further 6 months (344).  The only 1087 
RCT of rhGH at 0.45 mg/kg/wk, for improving linear growth in children with IBD, conducted 1088 
by Wong et al reported that HV increased by a median of 140% in the rhGH group compared 1089 
with an 8% reduction in the control group at six months [Fig 10]. Therapy over the six months 1090 
period was associated with a median difference of 3.3 cm of height gain between the rhGH 1091 
and control group; equivalent to a median relative gain in height SDS of +0.4SD (351). rhGH 1092 
therapy in this trial was associated with significantly higher levels of total IGF1, but no 1093 
significant changes in IGFBP-3, ALS, free IGF-1 and IGFBP-2 (352).Another RCT of rhGH 1094 
(0.53 mg/kg/wk) in children with CD designed to evaluate the role of rhGH in improving 1095 
disease process, showed that HV improved by 60% in the rhGH group at 12 weeks. Eighteen 1096 
of the 20 children who showed disease clinical remission at 12 weeks continued rhGH for a 1097 
total of 52 weeks. Ht SDS of this group improved from -1.1 to -0.4 (350).  1098 
Given the results of the preliminary studies of rhGH in children with IBD, there now 1099 
needs to be larger definitive trials of rhGH in slowly growing children. Challenges include 1100 
interpretation of growth rate during puberty and evaluation of disease activity. It is possible 1101 
that the growth response to rhGH may be more favorable in those with shorter duration of 1102 
disease and where nutrition is optimized. In that regard, future clinical trials of rhGH in IBD 1103 
should target those with shorter duration of disease since diagnosis and explore the benefit of 1104 
concurrent supplemental feeding.  1105 
 1106 
6.5 Factors affecting the growth response to rhGH in IBD 1107 
6.5.1 Disease and glucocorticoid 1108 
In IBD, HV was inversely related to pediatric crohn’s disease activity index (PCDAI) 1109 
and ESR. However, in individuals on rhGH but not the control group, HV showed a positive 1110 
association with hemoglobin, negative associations with ESR and PCDAI. Cumulative 1111 
prednisolone dose was not associated with growth response but the dose of prednisolone used 1112 
in that cohort was negligible (351).  1113 
 1114 
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6.5.2 Systemic IGF-1 1115 
In children with IBD treated with rhGH, IGF-1 showed a modest but weak 1116 
statistically significant association with growth rate during the period of treatment (351).  1117 
 1118 
6.6 Efficacy of rhGH in on disease process in IBD 1119 
Several animal models of colitis suggest a direct effect of rhGH on chronic 1120 
inflammation via a reduction of both mucosal apoptosis and IL-6 dependent signal transducer 1121 
and activator of transcription3 (STAT3) activation (173,174,353). rhGH can also directly alter 1122 
systemic markers of inflammation. rhGH in children with growth hormone deficiency (GHD) 1123 
may lead to reduction in systemic pro-inflammatory cytokines although the data of rhGH in 1124 
children with non-GHD states are conflicting (354-358). In a study by Slonim et al with the 1125 
primary aim of assessing the effects of rhGH treatment on reduction of inflammation, 32 1126 
adults with CD were randomized to rhGH (17 rhGH) or placebo injections for four months. 1127 
rhGH treatment was administered at 5mg daily for one week followed by 1.5 mg daily 1128 
thereafter. Reduction in Crohn’s disease activity index (CDAI) was significantly greater at 4 1129 
months with rhGH: -143 points in the rhGH group and -19 in the placebo group. There was 1130 
however no significant change in Hb, hematocrit (HCT), ESR, prealbumin, ferritin or iron 1131 
levels after 4 months (347).  1132 
To explore the role of rhGH on disease activity in pediatric CD, Denson et al 1133 
conducted an RCT in 20 children (19 rhGH) with CD (10 rhGH-0.53 mg/kg/wk). The 1134 
authors’ concluded that rhGH may be an adjunct for treatment of inflammatory disease based 1135 
on improvement in PCDAI (350). In the rhGH group, PCDAI was 32 and 8 points at baseline 1136 
and 12 weeks. In the control group, PCDAI was 33 and 22 at baseline and 12 weeks. The 1137 
percentage of GC usage in the rhGH group was lower at 12 weeks, although the dose of 1138 
prednisolone was similar in both groups. Other markers of disease activity including 1139 
endoscopic severity, fecal calprotectin and ESR were also similar. 1140 
Whilst generally accepted and validated as a disease index, there is a potential pitfall 1141 
in the use of PCDAI (359) in rhGH studies. PCDAI is made up of three domains:  1142 
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(1) Subjective patient recall of symptoms  1143 
(2) Laboratory parameters and clinical examination  1144 
(3) Auxology: weight and HV SDS. HV SDS accounts for 10 points if HV SDS < -1145 
2.0 SD, 5 points if < -1.0 SD but > -2.0 SD and 0 points if HV SDS > -1.0.  1146 
In the study by Denson et al, HV SDS was -1.0 and -1.8 at baseline in the rhGH and control 1147 
group. At 12 weeks, HV SDS was +2.0 and -2.1 in the rhGH and control group (350). We 1148 
believe that the lower PCDAI in the rhGH group in that study merely reflects improvement in 1149 
linear growth independent of reduction of inflammation. The possibility that rhGH may 1150 
improve inflammation directly in pediatric CD remains an open question but need to be 1151 
explored in future studies using other disease end points other than the PCDAI. 1152 
In the study by Wong et al. PCDAI was lower after 6 months therapy with rhGH 1153 
which could be interpreted as improvement in disease activity. However, when data was 1154 
analyzed using the abbreviated PCDAI which omits the laboratory, physical examination and 1155 
auxology domains, there was no difference in disease activity over the 6 months in both 1156 
groups. ESR, CRP, Hb, HCT, albumin, TNF, IL-1 and IL-6 were similar in both groups and 1157 
after the 6 months period (351). Extensive evaluation of 28 cytokines, chemokines and 1158 
inflammatory growth factor using the Multiplex assay in that clinical trial showed no 1159 
differences over the six months period in rhGH or control group and they also did not differ 1160 
between the two groups (352). Careful disease evaluation including the use of fecal 1161 
calprotectin, endoscopy or new imaging techniques like MRI should be considered in future 1162 
rhGH trials in IBD. 1163 
 1164 
7. Cystic fibrosis (CF) 1165 
7.1 Summary of disease and management 1166 
Cystic fibrosis (CF) is an autosomal recessive genetic condition, primarily affecting 1167 
the lungs but also the pancreas, liver, intestine and other organs. The defect is on the CF 1168 
transmembrane conductance regulator (CFTR) gene (7q31.2) on the long arm of chromosome 1169 
7 which leads to absence of normal CFTR protein which is a c-AMP activated ion channel. 1170 
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As a result of this, decreased chloride secretion and increased sodium absorption across 1171 
epithelial surface is seen. In the airways, this causes depletion of the airway surface liquid and 1172 
impaired mucociliary clearance which leads to pulmonary infection and inflammation of the 1173 
airways. This starts early in life and progresses to chronic infection and pulmonary 1174 
inflammation. Proteases, inflammatory cells and cytokines like IL-8, IL-6, TNF-α in 1175 
CF(360,361)may lead to ongoing airway wall inflammation, remodeling and eventually 1176 
bronchiectasis. Inflammatory mediators like neutrophil elastase and bacterial 1177 
lipopolysaccharide in turn mediate the inflammatory effects by activating the transcription 1178 
factor nuclear factor-κβ which regulates pathways that induce production of cytokines. 1179 
Pathogens such as Pseudomonas aeruginosa, Burkolderia cepacia, Staphylococcus aureus and 1180 
Haemophilus influenza eventually colonize the airway secretions of CF individuals.  1181 
Recent studies show that TNF gene polymorphism is associated with disease 1182 
progression and severity of pulmonary function (362,363), whilst another study found an 1183 
association with gene polymorphism in IL1-β, IL-8 and IL-10 to be associated with more 1184 
severe lung disease in CF (364). Cytokines in CF may also impact on the GH-IGF axis as 1185 
demonstrated in studies relating inflammatory cytokines to systemic markers of the GH axis. 1186 
In a group of young adults with CF, IL-6 was positively associated with IGFBP-2 (365). 1187 
Similarly, in a group of prepubertal children with CF, change in IL-6 was positively 1188 
associated with change in IGFBP-2 (366). 1189 
In CF, gastrointestinal symptoms and signs including failure to pass meconium in a 1190 
new born infant is seen. In severe instances this could be associated with meconium ileus in a 1191 
small proportion of infants. Exocrine pancreatic insufficiency occurs in the majority of 1192 
individuals and requires pancreatic enzyme supplementation. In CF with pancreatic 1193 
insufficiency, mucosal inflammation is often seen with raised fecal calprotectin. Fecal 1194 
calprotectin in CF is also associated with height SDS (367). Endocrine defects involving 1195 
damage to islet cells of the pancreas may lead to CF related diabetes. CF related diabetes with 1196 
features of both type 1 and type 2 diabetes mellitus is increasingly recognized especially in 1197 
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late adolescents. This is often parallels deterioration in lung function, growth and abnormal 1198 
bone development. 1199 
Current management of CF requires early treatment and prevention of pulmonary 1200 
infections with antibiotics, physiotherapy and nutritional support. Allergic bronchopulmonary 1201 
aspergillosis is an exaggerated immune response to Aspergillus fumagitus which is seen in 1202 
about 4-11% of individuals with CF, which will lead to worsening of lung function(368,369). 1203 
Oral GC is often used for prolonged periods as inhaled GC is not effective in this 1204 
condition(370). 1205 
Structured CF multidisciplinary services and easy access to health carers cognizant to 1206 
the issues in CF have improved clinical outcome in CF over the last few decades (371). With 1207 
increasing survival of people with CF, issues relating to growth and pubertal development 1208 
have become a greater concern.   1209 
 1210 
7.2 Growth failure in children with CF 1211 
Growth failure and short stature in CF may not have been given as much attention but 1212 
with the increasing age of survivial of these individuals, they may become more important 1213 
issues to consider. Severe short stature in CF may not be a common occurrence. In a recent 1214 
study of 169 children with CF in the Netherlands, prevalence of short stature was 8%. 1215 
However, when target height was taken into account, this was only 5%. When both delayed 1216 
maturation and target height were taken into account (height for bone age adjusted for target 1217 
height), this was only 1% (372). Similar to children with JIA and IBD, severe short stature in 1218 
contemporary groups of children with CF is uncommon although poor growth is still seen 1219 
(372).  1220 
Improved clinical care through multidisciplinary teams and the introduction of 1221 
neonatal screening for CF has been shown to be associated with improvement in growth. 1222 
Studies have shown that ongoing clinical care in specialist centers all throughout the life cycle 1223 
leads to improvement in growth parameters, although it is unclear which aspects of clinical 1224 
care is associated with improvement in growth. Interestingly, improvement in growth in those 1225 
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managed in specialist centers was not associated with in improvement in pulmonary function 1226 
(373,374). Most current published studies report some association between height and 1227 
pulmonary/pancreatic function (375-377) although other studies show no association of 1228 
growth with colonization with Pseudomonas aeruginosa (378) and respiratory function as 1229 
assessed by FEV1 (379), highlighting the multifactorial nature of poor growth in CF.  1230 
Addressing nutrition in CF is paramount and may improve linear growth in CF but 1231 
this needs to be assessed on an individual basis. Long term supplemental enteral feeding in 1232 
children with CF using gastrostomy feeding show improvement in height although height 1233 
often improves at least after 18 months of gastrostomy feeding (380-383). In a contemporary 1234 
group of children with CF, the prevalence of malnutrition was only 7%, whereas 15% were 1235 
overweight and 8% were obese (384) and therefore overzealous nutritional management 1236 
should be avoided 1237 
Evidence suggest that children with CF identified from screening exhibit better linear 1238 
growth compared with those diagnosed due to clinical symptoms (385). In a study of 89 CF 1239 
children identified from neonatal screening, one third of that cohort had height below the 3rd 1240 
centile and half of that cohort had height below the 10th centile (386) whereas in an older 1241 
study of children diagnosed from clinical symptoms, 40% had height below the 5th centile at 1242 
diagnosis (387). 1243 
With the introduction of neonatal screening, it is now recognized that infants with CF 1244 
are lighter, shorter and have smaller head circumference at birth (388-391), associated with 1245 
reduction in systemic IGF-1 levels from analysis of blood spot screening (171). CF genotype 1246 
itself may have an impact on growth and this is still poorly documented in current growth 1247 
studies in children and adolescents with CD. Children homozygous for ∆F508 mutation had 1248 
Ht SDS approximately 1 SD below the mean from infancy to early adolescence (392). Thus, 1249 
the condition itself via mechanism still unknown can predispose to growth failure and this 1250 
deserves further research. 1251 
Poor growth often precede the onset of CF related diabetes (23), and can impact on 1252 
pubertal growth and adult height (393).  Poor growth associated with CF related diabetes may 1253 
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not be normalized with insulin treatment even when started early (393), although currently 1254 
studies of insulin treatment in CF diabetes with linear growth outcomes are limited. CF 1255 
diabetes is often diagnosed in mid to late adolescents, although with increased awareness and 1256 
screening, diagnosis in childhood is not uncommon.  1257 
Short stature in CF may have an impact on disease severity as short stature in CF is 1258 
an independent predictor of mortality, which may reflect a sub- group with poorer nutrition or 1259 
low grade chronic inflammation and ongoing pulmonary exacerbations (394). A poorly 1260 
growing child with CF and short stature may also have lower lung reserve. The possible 1261 
benefit of rhGH therapy on pulmonary function in CF will be discussed in a later section. 1262 
Similar to children with IBD and JIA, pubertal abnormalities are also seen in children 1263 
with CF. Delay in skeletal maturation, onset of puberty, attenuated pubertal growth spurt has 1264 
been reported in adolescents with CF. Bone age was reported to be delayed by more than 24 1265 
months in 25% of adolescents and compared to healthy children, age of peak height velocity 1266 
as a marker of onset of puberty was delayed by 9-10 months in boys and 10-14 months in 1267 
girls. Girls with CF reach menarche 2 years later than their healthy peers (395). Older studies 1268 
show that delayed puberty is present especially in girls with CF despite good clinical status, 1269 
with an association of delayed pubertal onset especially in those with the ∆F508 mutation 1270 
(396). However, a recent retrospective study including  729 contemporary children with CF, 1271 
showed that delayed onset of puberty was not a common occurrence (379) 1272 
Adolescents with CF may have lower peak HV compared with healthy adolescents 1273 
with constitutional delay in growth and puberty (397). Those individuals with CF with 1274 
delayed puberty appear to also have poorer HV during pubertal progression (4,379). One 1275 
study reporting body proportions in a group of younger adolescents with CF showed that their 1276 
legs were shorter than trunks, although pubertal assessment was not reported (5). Delayed 1277 
puberty and short stature in CF correlated with less participation in social activities, which 1278 
may be related to the degree of pulmonary function and disease state. Delayed puberty in CF 1279 
was associated with poorer degree of ideal formation and less positive body attitude (398). 1280 
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Table 7 summarizes studies with information on AH in CF (4,379,388,399-403). 1281 
Interpretation of AH prognosis in CF from published studies is difficult given the fact that it is 1282 
possible that mortality in some of the more severely affected individuals in adolescence may 1283 
lead to more favorable AH of those studies with measurements conducted in adulthood. On 1284 
the other hand, survival and treatment have also improved over the last few decades.  1285 
The existing literature of growth in CF suggests that nutritional issues and pulmonary 1286 
exacerbations are not sufficient to explain the growth abnormalities in these children. There is 1287 
now sufficient evidence to suggest that poor growth in CF is already seen in the neonatal 1288 
period and that CF genotype (∆F508) plays a contributing role. Whether this is due to 1289 
underlying chronic inflammation or other unknown factors is yet to be determined. In 1290 
adolescence, further worsening of growth and pubertal disorders may herald the onset of CF 1291 
related diabetes and this requires early diagnosis and treatment, even though growth may not 1292 
fully normalize with insulin therapy. The complex interplay between CF genotype, 1293 
inflammation, nutritional and endocrine perturbations on growth requires further 1294 
investigation. The impact of CF neonatal screening on improvement in long term growth 1295 
outcome needs clarification.  1296 
 1297 
7.3 Systemic abnormalities in GH/IGF-1 axis in children with CF 1298 
In CF, it is generally accepted that GH resistance also exists although studies of GH 1299 
secretion is limited. Using arginine and clonidine as pharmacological stimulant of the GH axis 1300 
in a small group of adolescents with CF, approximately 50% had peak GH levels < 6 mcg/|L 1301 
and IGF-1 SDS -0.5, suggesting that relative GH resistance and GH insufficiency can occur. 1302 
It was unclear if sex steroid priming was used in this group of children with delayed puberty 1303 
as bone age was delayed at least by 2.5 years (404). 1304 
Low IGF-1 and IGFBP-3 have been previously reported in studies in children with 1305 
CF and show associations with pulmonary outcomes. In a study of a group of prepubertal and 1306 
pubertal children, IGF-1 SDS was -1.2 SD and IGFBP-3 SD was -0.7 during acute pulmonary 1307 
exacerbation, although another study reported low IGF-1 with normal IGFBP-3 (365). IGF-1 1308 
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correlated with forced expiratory volume 1 (FEV1) and forced vital capacity (FVC); whereas 1309 
IGFBP-3 correlated with FVC. (405).  In a group of prepubertal children with CF, systemic 1310 
IGF-1 and bioavailability of IGF-1 correlated with serum TNF-α, providing further evidence 1311 
to the role of inflammation on the GH-IGF axis in these children. Systemic IGF-1 showed an 1312 
association with height in children with CF although the relationship is modest at best 1313 
(366,406-408). In addition, systemic IGF-1 in CF may also be associated with weight, protein 1314 
catabolism (408), lean body mass (409) and pulmonary function (405,410). 1315 
Other studies report abnormalities in IGF binding proteins with normal systemic IGF-1316 
1 in CF in particular significantly lower IGFBP-3  and higher IGFBP-1 (406). Reduction in 1317 
bioavailability of IGF-1 due to abnormalities in IGF binding proteins could account for the 1318 
growth failure in CF (366,411) or alternatively “normal” IGF-1 in the face of growth failure 1319 
in CF could also point to IGF-1 resistance. The direct role of IGFP-1 on growth is unclear, 1320 
although it shows an association with insulin secretion in CF, suggesting that IGFBP-1 may 1321 
have a role in growth impairment via its effects on glucose homeostasis in CF (237). Changes 1322 
in IGF-1 and bioavailability of IGF-1 also correlated with progressive insulin deficiency 1323 
(412,413). Finally, IGFBP-2 has also been reported to be higher in CF compared to healthy 1324 
controls. Change in IGFBP-2 was associated with changes in IL-6 over a 12 months period 1325 
(366).  1326 
 In summary, systemic evaluation of the GH-IGF axis in CF have produced mixed 1327 
results. Low IGF-1 may be present in infants with CF within the first few weeks of life. The 1328 
interlink of IGFBP-1 with insulin secretion and IGFBP-2 with inflammation may provide 1329 
further insight into growth failure in CF, but comprehensive studies of the IGF axis and the 1330 
contribution to linear growth are needed. 1331 
 1332 
7.4 Efficacy of rhGH in CF 1333 
Clinical trials of the use of rhGH in CF have recently been evaluated in two 1334 
systematic reviews including meta-analysis of published studies (414,415). Both reviews have 1335 
included studies where height or growth rate were not reported as some of the published 1336 
 49 
studies have been powered to assess the effects of rhGH on metabolic consequences, body 1337 
composition and disease parameters.  1338 
For this review, we have focused on studies of rhGH in CF with growth outcomes: 1339 
Table 8 (416-421) and Table 9 (422-427). To date, there are 6 RCT of rhGH therapy on linear 1340 
growth in children with CF. The longest duration of rhGH clinical trials in CF currently in the 1341 
literature is 12 months. Change in Ht SDS with rhGH treatment over 12 months in CF range 1342 
from +0.2 to +0.6. The majority of published trials in CF have used rhGH at a dose of 0.3 1343 
mg/kg/wk. One RCT consisted of two treatment groups; a lower dose rhGH at 1344 
0.273mg/kg/wk and a higher dose rhGH at 0.49 mg/kg/wk in comparison to a untreated group 1345 
of controls (425). Both doses of rhGH in that study led to significantly better growth rate over 1346 
a short term period of 6 months but there appears to be a dose dependency of rhGH dose on 1347 
linear growth. It is worth noting that current clinical studies have excluded individuals with 1348 
CF who have abnormalities of glucose homeostasis/ CF related diabetes and those who are 1349 
colonized with Burkholderia cepacia. These reflect a sub-group of individuals who may be 1350 
more severely affected who may be more likely to present with growth failure in the clinical 1351 
practice to pediatric endocrinologists. It is therefore possible that rhGH may be less effective 1352 
in these individuals and care must be taken in extrapolating results of current clinical trials of 1353 
rhGH in CF when faced with clinical decisions of the role of rhGH in such individuals.  1354 
The three largest RCT of rhGH in CF all show that HV is approximately 150% higher 1355 
in the rhGH treated group compared with control/placebo (422,424,425). In the study by 1356 
Schnabel et al including two doses of rhGH, the “lower” dose of rhGH was comparable to the 1357 
dose used by Hardin et al (424) and Stavley et al (422). In that study, height velocity in the 1358 
group treated with the “higher” dose of rhGH of 0.49 mg/kg/week was approximately 180% 1359 
higher than the control group; whereas height velocity in the group treated with the “lower” 1360 
dose of 0.273 mg/kg/wk was approximately 150% higher than the control group (425)  1361 
The individuals included in the RCT by Schnabel et al (425) were in mid adolescents 1362 
as the inclusion criteria was bone age of 8-18 years, whereas the studies by Hardin et al (424) 1363 
and Stalvey et al (422) were younger, pre pubertal at baseline. Pubertal progression was 1364 
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reported by Stalvey et al (422) and did not differ between the rhGH and control group. Hardin 1365 
et al (424) and Schnabel et al (425) reported no progression in bone age over the treatment 1366 
period. No individual trial has reported response to rhGH depending on pubertal staging. In 1367 
the meta-analysis of pooled data by Phung OJ et al (414), prepubertal children appeared to 1368 
have greater increase in HV compared to pubertal children, whereas pubertal children appear 1369 
to have better weight gain than prepubertal children with CF treated with rhGH. In the trial by 1370 
Hardin et al a sub-analysis of change in Ht SDS was similar in those with Ht SDS < -2.2 and 1371 
those with Ht SDS > -1.2 (424). 1372 
Short term studies of up to 12 months in children and adolescents with CF, show 1373 
improvement in Ht SDS of +0.2 to +0.6 SD. However, none of the clinical trials have 1374 
included older adolescents with CF related diabetes and therefore the efficacy of rhGH in 1375 
these adolescents is unknown. Given the information that suggests that children with CF are 1376 
already shorter at birth and in infancy with low IGF-1 levels, there is a case to consider future 1377 
clinical trials of rhGH in younger children. Children with the ∆F508 genotype should also be 1378 
targeted for future rhGH studies given the strong link with growth failure in those with the 1379 
genotype. Compared with JIA and IBD, published trials of rhGH in CF have included 1380 
relatively large number of subjects but duration of follow-up is only 6-12 months. Conducting 1381 
clinical trials in these individuals can be challenging given the rest of the burden of clinical 1382 
care of CF and quality of life measures should be evaluated in future studies. 1383 
 1384 
7.5 Factors affecting growth response to rhGH in CF 1385 
7.5.1 Disease and glucocorticoid 1386 
Clinical studies of rhGH in CF have not related clinical outcome, pulmonary function 1387 
or GC use with responsiveness to rhGH therapy.  1388 
7.5.2 Systemic IGF-1 1389 
In CF, pooled data from subjects previously enrolled in clinical trials of rhGH 1390 
revealed that IGF-1 was significantly correlated with height and growth rate (408). 1391 
 1392 
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7.6 Efficacy of rhGH on disease process in CF 1393 
A role of rhGH in improvement of pulmonary disease in CF has been postulated to be 1394 
due to increase in absolute lung volume as a result of increased growth.  Another mechanism 1395 
could be due to improvement in lean body mass via the potential anabolic effect of rhGH.  In 1396 
individuals with CF, the ability of alveolar macrophages to kill Pseudomonas aueroginosa 1397 
was reduced compared with healthy controls and this was associated with reduction in lower 1398 
IGF-1 levels from broncho-alveolar lavage. Exposure of the macrophages to IGF-1 enhanced 1399 
their ability to kill Pseudomonas suggesting that the GH-IGF axis may have a role in 1400 
regulation of the immune system in CF (428). Preliminary evidence also suggest that IGF-1 1401 
may increase cystic fibrosis transmembrane conductance regulator which is defective in 1402 
individuals with CF, leading to altered airway composition and therefore pulmonary 1403 
infections (429). 1404 
In CF, several rhGH studies have shown a reduction in number of days of 1405 
hospitalization and the use of intravenous antibiotics (424,427). These are from studies which 1406 
did not include a placebo group. Current rhGH studies in CF have shown differing results on 1407 
objective measures of pulmonary function. One study noted significant improvement in 1408 
exercise tolerance measured by peak power output and VO2 max on cycle ergometer in the 1409 
rhGH treated children (426). Another rhGH study in a group of children and young adults 1410 
with CF (10-23 years) showed that maximal work load and VO2 max increased significantly 1411 
with rhGH therapy over 12 months (430). In randomized studies in CF, FVC and percentage 1412 
predicted FVC increased significantly in the rhGH group. FEV1 on the other hand increased 1413 
significantly in rhGH treated children but not percentage predicted FEV1.  1414 
It is generally accepted that pulmonary function should be reported as percentage 1415 
predicted (normalized to height). It is possible that improvement in pulmonary function may 1416 
not parallel improvement in height in the short term and that objective improvement in lung 1417 
function may happen later. In addition, a very short child with poor lung function may have a 1418 
relatively “normal” percentage predicted values as his/her lung function has been matched to 1419 
a younger shorter child, making interpretation of changes in pulmonary status in growth 1420 
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promoting studies difficult. Future studies should include newer methods of assessing 1421 
pulmonary disease in CF which are more sensitive to short term changes in respiratory status 1422 
and may not be related to body size. 1423 
 1424 
 8. Side effects of rhGH therapy in chronic disease 1425 
8.1 Glucose tolerance and insulin sensitivity 1426 
rhGH treatment has been reported to be associated with a decrease in insulin 1427 
sensitivity in some of the studies in children Turner syndrome (431,432), Prader Willi 1428 
Syndrome (433,434), small for gestational age (435) and idiopathic short stature (436). It may 1429 
also be associated with an increased risk of type 2 diabetes mellitus in children with risk 1430 
factors such as Turner Syndrome, Prader Willi Syndrome (437). Some of these conditions 1431 
themselves have an increased risk of reduction insulin sensitivity. 1432 
Children with inflammatory conditions may also be at risk of developing insulin 1433 
resistance as a result of the inflammatory process (438) as well as the use of concurrent GC 1434 
therapy (439). Approximately 50% of children with chronic rheumatic conditions on GC had 1435 
impaired glucose tolerance on oral glucose tolerance test (OGTT) (255)  In JIA, rhGH is 1436 
associated with reduction in insulin sensitivity, reflected by increased fasting and stimulated 1437 
insulin levels (261,263,268). In 43 children with JIA who had previously been treated with 1438 
rhGH, impaired glucose tolerance was observed in 37% and transient diabetes mellitus in 5%. 1439 
There was a higher incidence of impaired glucose tolerance in those who were treated late 1440 
possibly reflecting a longer duration of disease and greater exposure to exogenous 1441 
glucocorticoid. The two cases that developed frank diabetes were also overweight (440) .  1442 
In children with IBD, therapy with rhGH over a six months period led to increase in 1443 
fasting insulin with no abnormalities of glucose homeostasis. This cohort consisted of the 1444 
majority of individuals who have not been previously treated with GC.  Despite the fact that 1445 
fasting insulin levels increased following rhGH therapy in IBD, the clinical significance of 1446 
this is still unclear. The highest level of fasting insulin was 16 mU/L in a group of individuals 1447 
in mid and late adolescence (351). A recent consensus suggests that the threshold of fasting 1448 
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insulin for diagnosis of insulin resistance should be a level of ≥ 30 mU/L for those in tanner 1449 
stage 3 and 4; and ≥ 20 mU/L for those individuals in tanner stage 5 (441). 1450 
As mentioned previously, current clinical trials in CF have included individuals with 1451 
no abnormalities in glucose homeostasis and/or CF related diabetes. The impact of rhGH 1452 
treatment on glucose homeostasis in a child with CF and established diabetes is unknown. In 1453 
current clinical trials in CF, rhGH increases fasting glucose but there were no changes in post 1454 
prandial or peak glucose with OGTT. Increased fasting glucose was not seen in shorter term 1455 
rhGH studies (6 months). OGTT results were only available from short term 6 months studies. 1456 
HbA1C also did not change with rhGH therapy (414). However, given the glucose variability 1457 
in CF related diabetes, future studies should evaluate glucose homeostasis using continuous 1458 
glucose monitoring, which is increasingly recommended for diagnosis of CF related diabetes 1459 
(25,442). 1460 
To summarize this section, studies of the use of rhGH in children with chronic 1461 
disease treated with GC (JIA studies) show that its use may lead to impaired glucose tolerance 1462 
and type 2 diabetes in approximately 50% and 5% of treated individuals, respectively. In 1463 
published rhGH trials in IBD and CF, where use of GC is low, reduction in insulin sensitivity 1464 
is seen but no diabetes mellitus have been reported, although duration of rhGH treatment in 1465 
those studies are relatively short. The clinical significance of raised insulin especially in the 1466 
prepubertal child during rhGH treatment on long term metabolic outcome in these children is 1467 
unclear. The extent by which rhGH therapy can affect glucose homeostasis in individuals with 1468 
CF and established diabetes needs further exploration.  1469 
 1470 
8.2 Skeletal complications 1471 
Skeletal complications such as scoliosis (443), Legg-Calve-Perthes disease (444,445), 1472 
slipped capital femoral epiphysis (446,447)  and osteochondirtis (448) have been described in 1473 
children following commencement of rhGH therapy but systematic surveillance of the spine 1474 
especially in rhGH trials in children with chronic inflammatory disease has not taken place. In 1475 
one study, lumbar lordosis and scoliosis developed in similar numbers of rhGH and control 1476 
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subjects (5 in each group) with JIA (39). Only one patient with JIA treated with rhGH 1477 
developed hip osteochondritis (263); whereas there are no reports of Legg-Calve-Perthes 1478 
disease in JIA or IBD. Slipped upper femoral epiphyses have never been reported in this 1479 
group of patients. 1480 
There is a concern that the use of higher doses of rhGH may advance bone age and 1481 
accelerate pubertal progression but this has not been observed in children with JIA and IBD 1482 
(39,351). Age of onset of puberty in children with JIA with follow-up data at final adult 1483 
height did not differ between the rhGH and control group (39) 1484 
 1485 
8.3 Disease complications 1486 
The current published trials in children with chronic disease do not raise concerns 1487 
about rhGH worsening disease process. Previous studies in GHD and non GHD children 1488 
following rhGH injections suggest that the immune system may be activated although it is 1489 
unclear if the net effect is an up regulation or down regulation of inflammatory cytokines 1490 
(354-358). Six months therapy with rhGH was not associated with any significant changes in 1491 
a range of pro- and anti-inflammatory cytokines in children with IBD (Ref).  1492 
Intestinal fibrosis leading to strictures is a complication of CD, due to an excessive, 1493 
irreversible healing response to chronic inflammation. This is associated with overgrowth of 1494 
the muscularis mucosa, muscularis propria, excessive collagen deposition (449) and 1495 
mesenchymal cell hyperplasia (450).  In a rat model of colitis, rhGH was reported to stimulate 1496 
collagen accumulation in intestinal myofibroblasts (451)  but rhGH has also been reported to 1497 
reduce the severity of fibrosis via the induction of suppressor of cytokine signaling proteins 1498 
(452). There is a need to study this further especially when rhGH is administered in IBD. 1499 
 1500 
8.4 IGF-1 levels and cancer 1501 
The use of replacement rhGH therapy for GH deficiency in children previously 1502 
treated for childhood cancer has not been shown to be associated with tumor recurrence or 1503 
development of new tumors. The Childhood Cancer Survival Study (CCSS) identified an 1504 
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increased risk of meningioma in children treated with rhGH (453,454), although most of those 1505 
children had also received radiation to the brain which by itself could be associated with the 1506 
development of meningioma (453,454). In addition, the CCSS did not match rhGH treated 1507 
patients with rhGH naive patients matched for potential confounders for development of 1508 
second tumors. A recent study that matched for age, site of primary diagnosis, date of 1509 
radiotherapy, radiation dose and fractionation found no increased risk of tumor recurrence or 1510 
development of second tumors in rhGH treated patients (455).  1511 
An association between increased risks of malignancies has been reported in children 1512 
with JIA (456-458) and IBD (459,460)  which may seem to be unrelated to treatment with 1513 
immunomodulators and biologic therapy. Currently there are no reported associations 1514 
between cancer in children with JIA and IBD treated with rhGH. Patients with acromegaly 1515 
with excessively high GH and IGF-1 levels have an increased risk for thyroid, breast and 1516 
colorectal carcinoma (461-463) . Preliminary evidence also suggests that patients with IGF-1 1517 
deficiency due to genetic mutations in the GH receptor with very low/undetectable IGF-1 1518 
levels appear to be protected from cancer development (464). 1519 
 In JIA and IBD, rhGH leads to an increase in IGF-1 and IGFBP-3 levels. Bechtold et 1520 
al’s RCT of rhGH (0.33 mg/kg/wk) in JIA showed, reassuringly, that IGF-1 and IGFBP-3 1521 
remained within the normal reference ranges. Average IGF-1 SDS and average IGFBP-3 SDS 1522 
during rhGH were -0.93 and -0.24, respectively (39). Following rhGH (0.53 mg/kg/wk) for 1523 
active CD, IGF-1 SDS increased from -0.4 at baseline to +1.8 SD at 12 weeks and + 3.3 SD at 1524 
24 weeks. IGF-1 SDS was as high as +5SD at 24 weeks which is an issue to be of concern 1525 
(350) . 1526 
Even if systemic IGF-1 levels may not be excessively raised with relatively “high” 1527 
dose rhGH in children with chronic disease, there is the concern that systemic IGF-1 levels 1528 
may not reflect local expression of IGF-1 (465) . Animal models of colitis treated with rhGH 1529 
do not show increased expression of local IGF-1 (173,175). Suppressor of cytokine signaling 1530 
2 (SOCS2) which may be altered in chronic inflammation and which negatively regulates GH 1531 
action, has been reported to limit intestinal GH action (466,467) . It is possible that this may 1532 
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be a protective mechanism against high systemic IGF-1 (68,468). However, in the mouse 1533 
model, the protective effect of SOCS2 on the intestines was only seen in older animals. 1534 
Clearly, long term surveillance of rhGH treated patients with JIA, IBD and CF is crucial.  1535 
 1536 
9. IGF-1 and combined GH / IGF-1 in chronic inflammatory disease 1537 
As discussed, GH mediates its effects on target tissues via direct and indirect effects 1538 
(41). The direct effects of GH are those mediated via the GH receptor; indirect effects are 1539 
mediated largely via GH related peptides like IGF-1 but also IGF binding proteins. Whilst 1540 
systemic factors (GH and IGF-1) have independent effects on target organs like the growth 1541 
plate, local IGF-1 levels may play a more important role in regulation of longitudinal growth.  1542 
Given the possibility of a state of functional GH resistance with resultant secondary 1543 
IGF-1 insufficiency in chronic inflammation, rhIGF-1 maybe a therapeutic option for these 1544 
children (469). The use of rhIGF1 in children with primary IGF-1 deficiency due to mutations 1545 
in the GH receptor is effective in improving linear growth. As opposed to complete catch up 1546 
growth that is seen in children with GH deficiency treated with rhGH, children with primary 1547 
IGF-1 deficiency due to mutations in the GH receptor treated with long term rhIGF-1 still 1548 
remain significantly short (470,471).  1549 
Whilst there are currently no studies of rhIGF-1 in children with JIA or IBD, one 1550 
small randomized trial of rhIGF-1 (80 mcg/kg twice daily) compared with placebo, in 7 1551 
children with CF failed to show an effect on linear growth despite normalization of serum 1552 
IGF-1. The study showed a reduction in insulin sensitivity with rhIGF-1 treatment. The dose 1553 
of rhIGF-1 used in the study is within the recommended starting dose for children with 1554 
primary IGF-1 deficiency. Doses up to 120 mcg/kg twice daily, can be used in those children 1555 
(472). The lack of improvement of linear growth with conventional dose of rhIGF-1 in the 1556 
study with CF may point to a degree of functional IGF-1 resistance. Therefore, higher doses 1557 
of rhIGF-1 may be needed to be evaluated in future studies. The potential adverse effect of 1558 
hypoglycemia, may preclude the use of higher dose of rhIGF-1.  1559 
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Interestingly, systemic IGFBP-3 did not increase with rhIGF-1 in the study of 1560 
children with CF. On the other hand, some but not all studies of rhGH in chronic 1561 
inflammatory conditions have shown that IGFBP-3 can increase with rhGH treatment. rhIGF-1562 
1 may in fact reduce the level of IGFBP-3 and IGF-2 in children with idiopathic short stature 1563 
(473). IGFBP-2 did increase with rhIGF-1 treatment in those children. There is also the 1564 
theoretical possibility that rhIGF-1 administration may suppress endogenous GH secretion. In 1565 
TNBS rats with colitis treated with rhIGF-1, there was a rise in IGF1 levels and improved 1566 
linear growth linear growth, although growth rate was only 50% of those of control rats (138).  1567 
A trial of rhIGF1 in children with idiopathic short stature and “low” IGF1 who were 1568 
approximately 7 years at baseline, also raised the concern that rhIGF-1 may accelerate 1569 
skeletal maturation, which would be disadvantageous for adult height prognosis. Twelve 1570 
children (14.1%) in the two rhIGF-1 arms (80 mcg/kg and 120 mcg/kg twice daily) as 1571 
opposed to one (4.4%) in the control arm entered into puberty during the one year (473). This 1572 
is in contrast to the use of higher dose of rhGH in idiopathic short stature which does not lead 1573 
to increase in skeletal maturation and advancement of pubertal progression (474).  1574 
A pilot pharmacokinetic study of rh-IGF-1 at 120 mcg/kg/day in eight children with 1575 
severe CD lead to significant increase in systemic IGF-1 with almost half the cohort reaching 1576 
IGF-1 SDS > +2.0 (475). The authors developed a mathematical model that allows prediction 1577 
of a dose of rhIGF1 that could be used to maintain systemic IGF-1 below +2.5 SD of the 1578 
mean accounting for age, weight and PCDAI. Whether this mathematical model is valid over 1579 
a longer period of time where changes like growth and puberty may play a greater role is 1580 
unclear. In addition, given the fluctuating nature of CD, it is unclear how well the PCDAI 1581 
may reflect disease activity in this model. A randomized trial of dose titration of rhGH based 1582 
on systemic IGF-1 in children born small for gestational age show less favorable growth 1583 
response, although IGF-1 levels remained in the physiological ranges in the dose titrated 1584 
group (476) .  1585 
Given the importance of GH and IGF-1 in longitudinal growth, combined treatment 1586 
with rhGH and rhIGF-1 may be more physiological and beneficial for growth. Reports of 1587 
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combined use in humans show a higher serum concentration of IGF-1 in those who had 1588 
combined therapy versus those who had IGF-1 alone, possibly related to the negative 1589 
feedback effect of IGF-1 on pituitary GH secretion. A recent study in female rats, however  1590 
showed that combined rhGH and rhIGF1 therapy did not lead to further improvement in linear 1591 
growth despite an improvement in cortical bone mass  (57). On the other hand, in an 1592 
experimental rat model of uremia, combination therapy appears to be more effective than 1593 
rhIGF-1 or rhGH alone as growth promoting therapy (477). The addition of rhGH to rhIGF-1 1594 
may reverse the insulin suppressive effects of the latter and may have anti-catabolic effects on 1595 
protein synthesis and muscle mass in seven calorie restricted adults (478). Given the 1596 
uncertainties of the efficacy of high dose rhGH in improving muscle mass in children with 1597 
chronic inflammation thus far, combination therapy may confer advantages in that respect.  1598 
Combining rhGH with rhIGF-1 may prevent the glucose lowering effect of IGF-1 (478). Up 1599 
to 20% of children with idiopathic short stature treated with rhIGF1 120 mc/kg twice daily 1600 
were hypoglycemic (478). The use of IGF-1 may itself counter the insulin- resistant state that 1601 
may be induced by the use of high dose rhGH therapy in a group of children who may be 1602 
insulin resistant due to their state of chronic inflammation as well as the use of GC.  1603 
Given the evidence of relative GH resistance in children with chronic inflammation, 1604 
there is good biological rationale to explore the use of rhIGF1 on its own or in combination 1605 
with rhGH in future well designed collaborative RCTs.  1606 
 1607 
10. Summary and perspective 1608 
10.1 Clinical studies of growth and pubertal disorders  1609 
It is clear that clinical outome studies on growth, pubertal development and AH in 1610 
JIA, IBD and CF treated with contemporary treatment regimens are needed. Height, 1611 
especially AH, needs to be interpreted in the context of the child’s midparental height. As 1612 
degrees of delayed puberty can occur in these children, interpreting HV needs to be in the 1613 
context of bone age or pubertal staging. The use of change in Ht SDS may be a better method 1614 
of defining poor growth given the paucity of normative longitudinal data for HV. Ideally, 1615 
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newer studies should consider reporting growth problems in these children by describing Ht 1616 
SDS and change in Ht SDS or HV adjusted for bone age/puberty (372). Undoubtedly, studies 1617 
of AH are needed from contemporary groups of children with chronic disease, due to the 1618 
constantly changing landscape of therapies of chronic disease. Published data on AH may 1619 
never be reflective of current cohort of individuals managed in the clinic, given the time it 1620 
takes to acquire information on long term growth outcome and the possibility of new 1621 
therapies. 1622 
Outstanding questions in the clinical aspect of growth and pubertal disorders include: 1623 
(1) What are the clinical predictors of persistent growth failure in children with chronic 1624 
disease? Are there informative biomarkers eg disease parameters, inflammatory 1625 
cytokines, genetic factors or novel biomarkers early on in the course of the disease? 1626 
(2) What are early predictors for catch-up growth following anti-cytokine therapy in JIA 1627 
and IBD? What is the utility of systemic vs local markers of inflammation for 1628 
prediction of growth response? Can composite assessment of systemic inflammation 1629 
and systemic markers of the GH/IGF axis increase the prediction? 1630 
(3) How much does poor growth and pubertal disorders contribute to abnormal bone 1631 
accrual and muscle development in children with chronic disease?  1632 
(4) What is the impact of poor growth, short stature and delayed puberty on the quality of 1633 
life of adolescents with chronic disease and do they differ from children with no 1634 
underlying chronic condition? Are adolescents with chronic disease more bothered 1635 
about short stature/poor growth than delayed puberty? 1636 
 1637 
10.2 Systemic abnormalities of GH/IGF-1 in chronic disease 1638 
This review identified a number of heterogenous studies of the GH/IGF-1 axis 1639 
suggesting multiple defect in the secretion and sensitivity of the GH/IGF-1 axis. Studies have 1640 
evaluated IGF-1 and IGFBP-3, although ALS have not been extensively studied in these 1641 
conditions. 1642 
Important questions to be answered in this area include: 1643 
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(1) How does inflammation impact on formation of the ternary complex and how 1644 
does this change following therapy of chronic disease especially anti-cytokine? 1645 
(2) What is the link between inflammation and comprehensive studies of the ternary 1646 
complex? 1647 
(3) The direct role of IGF binding proteins on long bone growth in chronic disease is 1648 
unclear. We have touched on the possible role of IGFBP-1 and -2 which requires 1649 
further clarification. A consideration of the differential effects of all the binding 1650 
proteins in chronic disease is needed. For instance, is there compensatory changes 1651 
in IGF binding proteins with chronic inflammation and what is the impact on 1652 
regulation of growth in chronic disease? 1653 
(4) What is the IGF-1 response to rhGH injections as part of the IGF- generation test 1654 
and how does this GH sensitivity change with disease factors? 1655 
 1656 
10.3 Growth plate regulation in chronic disease 1657 
 Recent growth plate studies have demonstrated that pro-inflammatory cytokines have 1658 
a direct effect at the level of the growth plate. GC treatment and malnutrition can lead to 1659 
impairment at the level of the growth plate.  1660 
Critical research questions to be answered in this area which may impact on clinical 1661 
management and research include: 1662 
(1) How does cytokine, GC and malnutrition impact on local GH and IGF-1 1663 
signalling? 1664 
(2) How do intrinsic growth plate factors interact with extrinsic systemic factors in 1665 
the regulation of growth in chronic disease? 1666 
(3) What is the role of IGF binding proteins at the local level in chronic disease? 1667 
(4) What is the interaction between FGF21 and cytokines and how may that impact 1668 
on local bone growth/local growth factor signalling? 1669 
 1670 
10.4     Endocrine growth promoting therapies in chronic disease 1671 
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There is a need to perform larger, more conclusive studies of rhGH therapy which 1672 
explore the issues raised in this review. Close collaboration with pediatric rheumatologists, 1673 
gastroenterologists and respiratory clinicians would ensure that appropriate assessment of 1674 
disease status is performed. Given the complexity of the management of children with chronic 1675 
disease and ongoing burden of the disease, the opinion of the young person and their families 1676 
should be sought in the design of future therapeutic trials of growth promoting therapies.  1677 
Disease activity should be assessed using a range of methods. For CD, caution is 1678 
needed if the PCDAI is used. Data should be presented for the different domains of the 1679 
PCDAI, if that is to be used as a disease marker. In CF, more objective assessment of disease 1680 
should be evaluated in future studies other than hospitalizations. Evaluation of inflammatory 1681 
state using inflammatory cytokines should include assessment of more than 1 cytokine and in 1682 
addition measurements of cytokines at local organs (eg gastrointestinal tract, synovial fluid) 1683 
may be more accurate but more challenging to obtain in research studies. 1684 
Research agenda to be considered include:  1685 
(1) A definitive trial of rhGH on improving growth in children with chronic disease 1686 
especially in children with IBD is needed. This would require collaboration at a 1687 
national level at the least.  1688 
(2) It is clear that a degree of functional GH insensitivity exists in chronic disease 1689 
and a higher dose of rhGH may be needed. A study on dose comparison 1690 
addressing longer term growth outcome and potential adverse events 1691 
(abnormalities in glucose homeostasis) in these groups of children are needed. 1692 
Preliminary evidence from the dose comparison trial of rhGH in CF suggest that 1693 
the percentage increase in growth rate with the “higher” dose of rhGH leads to 1694 
marginal improvement in growth velocity (425) .  1695 
(3) It is unclear whether the dose of rhGH should be titrated by systemic IGF-1 or 1696 
growth response and this requires further research. 1697 
(4) It is possible that in most children a short course of therapy for 12 months or 1698 
during periods of poor growth may be sufficient for improving growth and 1699 
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prolonged therapy may not be necessary. Intermittent therapy with rhGH during 1700 
periods of relatively poor growth may also be more cost effective. This method of 1701 
using rhGH as opposed to continued use until final height needs further 1702 
exploration. 1703 
(5) Future rhGH studies should also examine the effect of therapy on disease, bone 1704 
health, body composition, cardiovascular health and quality of life in these 1705 
children with chronic disease. It is also unclear if long term outcome of addition 1706 
of rhGH to sex steroid confers better height prognosis in those groups of children 1707 
who are growing slowly with delayed puberty.  1708 
(6) Given that some children with chronic disease continue to grow slowly with anti-1709 
cytokine therapy (18) and that improvement in height with anti-cytokine maybe 1710 
marginal (21,219), the role of rhGH in addition to anti-cytokine therapy should 1711 
also be explored in future studies 1712 
(7) The impact of pubertal induction on growth in chronic disease deserves higher 1713 
research priority. There are numerous unanswered questions on the dose, 1714 
duration, route of administration and timing of introduction of sex steroid in 1715 
chronic disease.  1716 
(8) Given the relative GH resistant state in chronic inflammation, the role of 1717 
combination therapy of rhIGF-1 with rhGH or rhIGF-1 on its own may need to be 1718 
explored in future well designed trials. 1719 
(9) Given the range in deficits in systemic levels of GH/IGF-1 in chronic disease, can 1720 
these be used to determine choice of growth promoting therapies ie rhGH, rhIGF-1721 
1 or combination therapies and therefore growth response? 1722 
 1723 
11. Recommendations for clinical practise 1724 
In the absence of extensive data, the off label use of rhGH in chronic disease in 1725 
countries where rhGH may be available needs to be considered very carefully and discussed 1726 
thoroughly with the young person and the family. rhGH therapy should only be considered 1727 
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after the primary disease has been treated as aggressively as possible, GC use has been 1728 
minimized and the nutritional status has been optimized. In patients with delayed puberty, this 1729 
should be addressed before the consideration of rhGH, although data on pubertal induction in 1730 
these children is limited (479,480).  If rhGH is used, the definition of response in children 1731 
with chronic disease is unclear but may be better defined as change in Ht SDS (> +0.5 SD 1732 
over twelve months).  1733 
It is our opinion that fasting glucose and HbA1C should be considered in all children 1734 
with chronic disease prior to commencement of rhGH therapy. Ideally, an OGTT should be 1735 
performed at baseline as well. Given the challenges in interpretation of insulin levels in 1736 
groups of children who are in puberty, there is a case to omit its measurement in the clinical 1737 
monitoring of children with chronic disease treated with rhGH therapy. It is our opinion that 1738 
results from an OGTT may be more useful for clinical decision making and should therefore 1739 
be perfomed at annual intervals following rhGH therapy as fasting glucose and HbA1C are 1740 
poor predictors of abnormal glucose homeostasis in children with chronic disease treated with 1741 
rhGH (Simon 2010). In CF, there may be a role of continuous glucose monitoring for 1742 
monitoring of glucose homeostasis. In children with evidence of diabetes (eg CF diabetes) or 1743 
impaired glucose tolerance at baseline, there needs to be careful discussion with the family 1744 
regarding the risk and benefit of rhGH therapy. In our opinion, the detection of impaired 1745 
glucose tolerance requires reconsideration of therapy. If oral GC dose can be reduced, we 1746 
recommend close monitoring with earlier re-evaluation with OGTT. If this is not possible, or 1747 
type 2 diabetes mellitus is diagnosed on OGTT, reduction of dose of rhGH is recommended, 1748 
provided that grwth response is favourable.  1749 
Annual assessment of IGF-1 level should be undertaken but interpretation of IGF-1 1750 
levels needs to take into account of delayed puberty in these children. Regular assessment of 1751 
puberty and annual bone age is also important. Care must be taken in the interpretation of 1752 
bone age in children with inflammatory arthritis. Ideally, this should be performed in the hand 1753 
not affected by arthritis. 1754 
 1755 
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12.  Conclusion 1756 
The pathophysiology of growth failure in children with chronic inflammation is 1757 
multi-factorial although the precise mechanism of the effects of cytokine, glucocorticoid and 1758 
malnutrition on systemic and local growth factors is still unclear. The relative contribution of 1759 
those factors on growth failure and the GH/IGF axis is unclear. Clinical studies in children 1760 
with JIA, IBD and CF point to multiple levels of defect of the GH/IGF-1 axis although 1761 
comprehensive evaluation of systemic growth factors in these children especially in relation 1762 
to modern therapy is still limited. The interaction of the endocrine effects of the GH/IGF-1 1763 
axis with local growth plate regulating factors and the impact on linear growth in chronic 1764 
disease is unclear and needs to be studied.  1765 
Although there is some preliminary evidence of the effects of rhGH on short term 1766 
linear growth in children with chronic disease, catch-up growth maybe incomplete. Longer 1767 
term treatment studies and its effects on adult height in these children should be performed. 1768 
The impact of improvement in linear growth on quality of life in these children is unknown. 1769 
The cost effectiveness and implication of treatment (burden of injections) needs careful 1770 
consideration.  Most children with chronic inflammatory disease will achieve their genetic 1771 
potential with aggressive disease control and nutritional support. A small subgroup may have 1772 
persistent growth failure leading to significant short stature and these children may benefit 1773 
from adjuvant growth promoting therapy. Collaborative clinical trials and translational studies 1774 
are needed and to be encouraged.  1775 
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Figure 1: Age Of Presentation Of Chronic Disease In Childhood 
CF: cystic fibrosis, DMD: duchenne muscular dystrophy; JIA: juvenile idiopathic arthritis; 
CRI: chronic renal insufficiency; IBD: inflammatory bowel disease; SLE: systemic lupus 
erythematosus; CTD: connective tissue diseases 
!
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Figure 2: Mechanism Of Growth Failure In Chronic Inflammatory!Disease!
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GH:!growth!hormone;!IGF:!insulin!like!growth!factor!
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Fig 3: Multiple Level Of Defect Of the GH/IGF-1 Axis In Children With Chronic Disease 
GH: growth hormone; IGF-1: insulin like growth factor-1; IGFBP: insulin growth factor binding protein 
!Figure 4: Effects Of TNFα And IL1β On ATDC5 Cell Line Chondrogenesis 
 
MacRae VE et al J Endocrinol 2006; 189: 319-28  71 
!
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!Figure 5: Effects of TNFα and IL1β in the metatarsal model depending on days of exposure to cytokine 
 
MacRae Ve et al J Endocrinol 2006; 189: 319-28 71 
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Figure 6a: Effects of addition of antibodies to metatarsals exposed to TNFα and IL1β        
Martensson K et al J Bone MinerRes 2004; 19:1805-12 73 
!
!
Figure 6b: Effects of addition of antibodies to metatarsals exposed to synovial fluid of a 
child with systemic JIA during acute relapse 
MacRae VE et al Clin Endocrinol 2007; 67:442-8 86 
PBS: phosphate buffered solution; SF-A: synovial fluid from child A; Ab: antibody 
!
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!
 
Figure 7:  Synchronized mean growth curves from baseline to adult height in 13 children with 
JIA treated with rhGH (solid lines) in comparison with 18 controls (dashed lines) 
Bechtold S et al J Clin Endocrinol Metab 2007; 92: 3013-8 39 
!Figure 8: Height SDS In Children And Adolescent With IBD And Body Image Domain Score On 
IMPACT III Questionnaire 
 
(Mason A et al Horm Res Pediatr 2014; 83:45-54) 
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Figure 9: Peak Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF1) To Insulin 
Tolerance Test (ITT) In Children With Inflammatory Bowel Disease (IBD). 
IGF1: insulin-like growth factor 1, GH: growth hormone, SDS: standard deviation score.  
Grp A: Peak GH < 3 mcg/l, IGF1 SDS < 0 (Functional GH deficiency).  
Grp B: Peak GH < 6 mcg/l but ≥3 mcg/l, IGF1 SDS < 0 (Functional GH insufficiency).  
Grp C: Peak GH ≥ 6 mcg/l, IGF1 SDS < 0 (Functional GH resistance).  
Grp D: IGF1 SDS ≥ 0 (Functional GH-IGF1 resistance).  
Wong SC et al Clin Endocrinol 2011; 74: 599-607 338 
!Figure 10:  Height velocity (HV) and height SDS before and after 6 months of therapy with recombinant human growth hormone 
(rhGH) or no therapy (Ctrl) in inflammatory bowel disease.  
HV: P = 0·003 (rhGH – baseline vs6 months), P = 0·58 (Ctrl – baseline vs 6 months) Ht SDS: P = 0·003 (rhGH – baseline vs 6 months),P = 0·14 (Ctrl – baseline vs 6 months). 
Wong SC et al Clin Endocrinol 2011; 74:599-607 351 
  
No patients 
 
Age at assessment  
 
 
Adult height result 
 
Deviation from mid-parental height 
 
Gare et al 
(1995) 232 
 
 
124 
(33 oligo, 58 poly, 2 systemic, 30 others) 
 
 
18 yrs 
 
Females 165.9 cm, males 176.9 cm 
 
ND 
Zak et al 
(1999) 233 
 
65 
(21 oligo, 39 poly, 5 systemic) 
26 yr Ht SDS -0.3 (11% Ht SDS < -2.0) ND 
Minden et al 
(2002) 195 
 
215 
(85 oligo, 30 poly, 30 systemic, 30 others) 
23 yrs Females 166 cm, males 179 cm ND 
Packham et al 
(2002) 236 
 
259 
(70 oligo, 78 poly, 52 systemic, 61 others) 
28 yrs Ht SDS females -1.1 
Ht SDS males -0.7 
ND 
Wang et al 
(2002) 234 
 
33 
(7 oligo, 18 poly, 8 systemic) 
  20 yrs 
 
Infrequent GC 165.6 cm 
Intermittent GC 165.8 cm 
Prolonged GC 147.6 cm 
 
Infrequent GC +3.0 cm above MPH 
Intermittent GC +1.0 cm above MPH 
Prolonged GC -12.0 cm from MPH 
Simon D et al 
(2002) 204 
 
24 systemic 25 yrs Ht SDS -2.0 
41% Ht SDS < -2.0 
-1.7 SD below MPH SDS (87% below MPH SDS) 
Minden et al 
(2009) 235 
 
141 JIA 
 
18 ys Females 165 cm, males 176 cm 
Female poly Ht SDS -0.5 
Males poly Ht SDS -0.6 
Females systemic Ht SDS -0.5 
Males systemic Ht SDS -2.1 
 
ND 
 
Table 1: Published Studies Of Adult Height In Childhood Onset Juvenile Idiopathic Arthritis 
JIA: juvenile idiopathic arthritis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; GC: glucocorticoid; MPH: mid-parental height 
 
  
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age baseline 
(yrs) 
 
HV baseline 
(cm/yr) 
 
HV follow-
up (cm/yr) 
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change Ht 
SDS 
 
 
Butenandt et 
al (1979) 256 
 
 
Retrospective 
 
20 
 
Variable 
 
0.18 
 
13.0 
 
2.7 
 
6.2 (1st yr) 
 
130% 
 
- 
 
- 
 
- 
Svantesson et 
al (1991) 259 
 
Retrospective 6 Variable 0.16-0.46 13.7 2.8 6.7 (1st yr) 139% -3.4 - - 
Davies et al 
(1994) 257 
(1997) 244 
 
Prospective 10 low dose 
10 high dose 
1.0 0.15 
0.30 
9.2 
10.6 
2.4 
2.0 
4.5 
6.1 
88% 
205% 
-3.0 
-3.4 
- - 
Touati et al 
(1998) 260 
 
Prospective 14 1.0 0.46 10.8 1.9 5.4 184% -4.3 -4.3 0 
Al-Mutair et 
al (2000) 254 
 
Retrospective 10 Variable 0.16-0.30 11.9 2.5 4.8 (1st yr) 
5.4 (2nd yr) 
92% 
116% 
- - - 
Simon et al 
(2003) 258 
 
Prospective 14 3.0 0.46 12.5 2.0 6.0 (1st yr) 
5.0 (2nd yr) 
4.1 (3rd yr 
 
200%  
150% 
105% 
-4.6 -4.5 (1st yr) 
-4.3 (2nd yr) 
-4.3 (3r yr) 
+0.1 
+0.3 
+0.3 
Bechtold et al 
(2004) 255 
 
Prospective 11 4.0 0.25-0.33 10.3 - - - -3.9 -2.1  +1.8 
 
Table 2: Published Non Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With Juvenile 
Idiopathic Arthritis 
yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard deviation 
score 
 
  
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age 
baseline 
(yrs) 
 
HV baseline 
 
 
HV follow-up  
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change Ht 
SDS 
 
 
Bechtold et al 
(2001) 266 
 
 
RCT 
 
14 rhGH 
5 rhGH (GHD) 
16 Ctrl 
 
 
2.0 
 
0.33 
0.16 
 
9.7 
10.5 
7.8 
 
-2.9 SD 
-3.1 SD 
-3.2 D 
 
+0.3 SD 
-0.5 SD 
-1.2 SD 
 
- 
 
-3.7 
-2.6 
-2.9 
 
-2.9 
-2.4 
-3.2 
 
+0.8 
+0.2 
-0.3 
Bechtold et al 
(2003) 265 
 
RCT 18 rhGH (9GHD) 
 
20 Ctrl 
4.0 0.33 
 (0.20 for GHD) 
10.5 
 
9.6 
2.4 cm/yr 
 
2.3 cm/yr 
4.7 cm/yr 
 
3.4 cm/yr 
96% 
 
48% 
-3.3 
 
-2.3 
-2.3 
 
-3.0 
+1.0 
 
-0.7 
Saha et al 
(2004) 250 
 
RCT  
(Cross-over 
trial rhGH vs 
placebo) 
 
24 0.5 0.23 9.0 - +2.0 SD (rhGH) 
-0.1 SD (placebo) 
- -2.1 
-2.2 
-1.9 
-2.0 
+0.2 
+0.2 
Grote et al 
(2006) 267 
 
RCT 10 rhGH 
7 Ctrl 
 
2.0 0.32 8.0 
8.1 
- - - -1.4 
-1.9 
-1.0 
-2.1 
+0.4 
-0.2 
Simon et al 
(2007) 268 
 
RCT 15 rhGH 
15 Ctrl 
3.0 0.47 5.6 
5.7 
2.7 cm/yr 
2.6 cm/yr 
6.5 cm/yr 
5.0 cm/yr 
141% 
85% 
-1.1 
-1.0 
-0.4 
-1.8 
+0.7 
-0.8 
Bechtold et al 
(2007) 39 
 
RCT 13 rhGH 
18 Ctrl 
13.7 
14.4 
0.33 4.8 
4.0 
-2.2 SD 
-2.6 SD 
- - -2.7 
-3.5 
-1.6 
-3.4 
+1.1 
+0.1 
 
Table 3: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Juvenile 
Idiopathic Arthritis 
RCT: randomized controlled trials; yrs; years; rhGH: recombinant hman growth hormone; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: 
height; SDS: standard deviation score 
 
  
No patients 
 
Age at assessment 
 
 
Adult height result 
 
Deviation from mid-parental height 
 
Castile et al 
(1980) 316 
 
 
177 CD 
 
23 yrs 
 
Medically managed Ht SDS -0.6 
Surgically managed Ht SDS -0.3 
 
ND 
Griffiths et al 
(1993) 3 
 
67 CD 17 yrs and HV < 1 cm/yr Females Ht SDS -0.5 
Males Ht SDS -1.0 
ND 
Markowitz et 
al (1993) 317 
 
48 IBD 
(38 CD, 10 UC) 
21 yrs CD: 56% < 25th centile 
UC: 25% < 5th centile 
 
ND 
Hildebrand et 
al (1994) 303 
124 IBD 
(46 CD, 60 UC18 IBDU) 
 
>16 yrs or HV < 0.5 cm/yr CD Ht SDS +0.4 
UC Ht SDS +0.2 
IBDU Ht SDS -0.1 
 
ND 
Ferguson et al 
(1994) 314 
 
70 IBD 
(50 CD, 20 UC) 
                     ND CD males 175 cm, CD females 157 cm 
UC males 175 cm, UC females 159 cm 
ND 
Alemazedeh et 
al (2002) 318 
 
135 CD ≥ 18 yrs Prepubertal onset Ht SDS -1.0 
Pubertal onset -0.1 
Adult onset +0.1 
 
Prepubertal onset 2.1 cm below MPH 
Pubertal onset 0.6 cm above MPH 
Adult onset 0.9 cm above MPH 
Sawczenko et 
al (2003) 8 
 
43 CD > 16 yrs Ht SDS -0.7 5.9 cm below MPH 
Sawczenko et 
al (2006) 9 
 
123 CD HV < 1 cm/yr Ht SDS -0.3 3 cm below MPH but 20% were ≥ 8 cm below MPH 
Lee et al 
(2010) 319 
 
141 IBD ≥ 18 yrs “Growth impaired” Ht SDS -1.3 
“Not growth impaired” Ht SDS -0.1 
“Growth impaired” -0.7 SD lower than MPH SDS 
“Not growth impaired” -0.1 SD lower than MPH SDS 
Table 4: Published Studies Of Adult Height In Childhood Onset Inflammatory Bowel Disease 
IBD: inflammatory bowel disease; CD: crohn’s disease; UC: ulcerative colitis; IBDU: inflammatory bowel disease unclassified; Ht: height; cm: centimeter; SDS: standard 
deviation score; ND: no details; MPH: mid-parental height 
                           
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age 
baseline 
(yrs) 
 
HV baseline 
 
 
HV follow-up  
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change 
Ht SDS 
 
 
McCaffery et 
al (1974) 342 
 
 
Retrospective 
 
2 
 
0.5 
 
10 mg for 5 days 
then 3 mg three 
times per week 
 
 
- 
 
6.5 cm/yr 
 
9.2 cm/yr 
 
42% 
 
- 
 
- 
 
- 
Henker et al 
(1996) 343 
 
Retrospective 3 2.0 0.9-1.0 mg daily 16.2 5.0 cm/yr 10.4 cm/yr 108% -3.4 -1.6 +1.8 
Mauras et al 
(2002) 344 
 
Prospective 10 0.5-1.0 0.35 11.9 4.0 cm/yr 7.4 cm/yr (1st yr) 85% - - - 
Wong et al 
(2007) 345 
 
Retrospective 7 Variable 0.15-0.31 15.9 2.5 cm/yr 3.7 cm/yr (0.5 yrs) 48% -2.2 -1.9 +0.3 
Heyman et al 
(2008) 346 
 
Prospective 8 rhGH 
24 historical Ctrl 
1.0 0.30 12.6 
12.5 
3.0 cm/yr 
4.0 cm/yr 
8.3 cm/yr 
4.9 cm/yr 
177% 
23% 
-2.0 
-1.8 
-1.2 
-1.6 
+0.8 
+0.2 
Slonim et al 
(2009) 348 
 
Retrospective 4 4.5-7.5 0.18-0.20 13.8 - - - -3.5 -1.9 +1.6 
 
Table 5: Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With 
Inflammatory Bowel Disease 
yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard 
deviation score 
 
                           
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age baseline 
(yrs) 
 
HV baseline 
 
 
HV follow-up  
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change Ht 
SDS 
 
Calenda et al 
(2005) 349 
 
RCT 
(Placebo 
cross-over) 
 
3 rhGH 
4 Ctrl (placebo) 
1.0 0.35 11.0 - - - - - +0.1 SD 
+0.2 SD 
Denson et al 
(2010) 350 
 
RCT 10 rhGH 
10 Ctrl 
0.25 0.53 12.0 
13.0 
- +2.0 SD 
-2.1 SD 
 
- - - - 
Wong et al 
(2011) 351 
 
RCT 11 rhGH 
11 Ctrl 
0.5 0.45 14.7 
13.7 
4.5 cm/yr 
3.8 cm/yr 
10.8 cm/yr 
3.5 cm/yr 
140% 
-7.9% 
-2.8 
-1.8 
-2.5 
-1.9 
+0.3 
-0.1 
 
Table 6: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Inflammatory Bowel Disease 
RCT: randomized controlled trial; yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height 
velocity; Ht: height; SDS: standard deviation score; SD: standard deviation 
 
  
No patients 
 
Age at assessment  
 
 
Adult height result 
 
Deviation from mid-parental height 
 
Hauesler et al 
(1994) 388 
 
 
139 
 
19 yrs 
 
Males 173 cm (25th centile) 
Females 161.5 cm (25th centile) 
 
 
ND 
Morrison et al 
(1997) 403 
  
1604 males 
1452 females 
20 yrs Males Ht SDS -0.7 
Females Ht SDS -0.9 
ND 
Lai et al (1999) 
399 
 
30 Males 19 yrs 
Females 17 yrs 
 
Males Ht SDS -1.2 
Females Ht SDS -0.1 
48% below MPH 
Aswani et al 
(2003) 400 
 
US: 27349 males, 23797 females 
Canada: 4315 males, 3816 females 
≥ 25 yrs 25th centile ND 
Assael et al 
(2009) 401 
112 “mild disease” 
112 “ severe disease” 
 
> 20 ys “Mild disease “ males 172.4 cm 
“Mild disease” female  161.3 cm 
“Severe disease” males 171.1 cm 
“Severe disease” females 160.1 cm 
 
ND 
Boumez et al 
(2012) 379 
 
398 males 
331 females 
19 yrs Males Ht SDS -0.7 
Females Ht SDS -0.5 
ND 
Djik et al 
(2011) 402 
 
38 clinical diagnosis 
41 neonatal screening 
18 yrs Clinical diagnosis -1.2 
Neonatal screening -0.2 
ND 
Zhang et al 
(2013) 4 
 
1862 
(269 with parental height) 
21 yrs 160 cm (28th centile) MPH 53d centile 
 
Table 7: Published Studies Of Adult Height In Childhood Onset Cystic Fibrosis 
CF: cystic fibrosis; Ht: height; cm: centimeter; SDS: standard deviation score; ND: no details; MPH: mid-parental height 
 
                           
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age 
baseline 
(yrs) 
 
HV baseline 
 
 
HV follow-up  
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change 
Ht SDS 
 
 
Huseman et 
al (1996) 420 
 
 
Prospective 
 
9 
 
1.0 
 
0.30 
 
7.0 
 
5.7 cm/yr 
 
7.8cm/yr 
 
37% 
 
-1.3 
 
-0.8 
 
+0.5 
Hardin et al 
(1997) 417 
 
Retrospective 24 1.0-2.0 0.29 10.3 3.7 cm/yr 7.8 cm/yr (1st yr) 
6.5 cm/yr (2nd yr) 
111% 
76% 
-3.2 - - 
Alemzadeh et 
al (1998) 419 
 
Prospective 15 2.0 0.35 3.2 - - - -2.8 -0.9 +1.9 
Hardin et al 
(1998) 419 
 
Prospective 9 1.0 0.35 5.4-12.2 5.6 cm/yr 8.0 cm/yr 43% -1.9 -1.3 +0.6 
Sackey et al 
(1998) 421 
 
Prospective 7 1.0 0.16 7.9 0.3 cm/yr 4.1 cm/yr (0.5 yrs) 1141% - - - 
Hardin et al 
(2005) 416 
 
Retrospective 13 rhGH 
12 historical Ctrl 
1.0 0.30 13.8 
14.3 
5.1 cm/yr 
5.0 cm/yr 
8.0 cm/yr 
5.0 cm/yr 
57% 
0% 
-1.9 
-1.9 
- - 
 
Table 8: Published Non-Randomized Studies Of Recombinant Human Growth Hormone On Linear Growth In Children With Cystic 
Fibrosis 
yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard 
deviation score 
 
                           
Study design 
 
No patients 
 
Duration 
(yrs) 
 
rhGH dose 
(mg/kg/wk) 
 
Age 
baseline 
(yrs) 
 
HV baseline 
 
 
HV follow-up  
 
% change 
HV 
 
Ht SDS 
baseline 
 
Ht SDS 
follow-up 
 
Change 
Ht SDS 
 
 
Hardin D et 
al (2001) 423 
 
 
RCT 
 
10 rhGH 
9 Ctrl 
 
1.0 
 
0.30 
 
10.2 
11.4 
 
3.9 cm/yr 
4.0 cm/yr 
 
8.0 cm/yr 
4.0cm/yr 
 
105% 
0% 
 
-0.5 
-0.6 
 
-0.3 
-0.9 
 
+0.2 
-0.3 
Hutler et al 
(2002) 426 
 
RCT 6 rhGH 
4 Ctrl 
0.5 0.27-0.35 12.1 - 9. cm/yr 
5.4 cm/yr 
- 139 cm 
139cm 
141.1 cm 
143.3 cm 
- 
Hardin et al 
(2005) 427 
 
RCT 9 rhGH 
9 Ctrl 
1.0 0.30 11.6 
11.1 
- 8.0 cm/yr 
3.8 cm/yr 
- -1.7 
-1.7 
-1.1 
-1.7 
+0.6 
0.0 
Hardin et al 
(2006) 424 
 
RCT 32 rhGH 
29 Ctrl 
1.0 0.30 10.3 
9.7 
- 8.0 cm/yr 
5.0 cm/yr 
- -1.8 
-1.9 
- - 
Schnabel et al 
(2007) 425 
 
RCT 20 high dose 
22 low dose 
21 Ctrl (placebo) 
 
0.5 0.49 
0.27 
14.3 
13.8 
14.6 
- 6.8 cm/yr 
5.6 cm/yr 
3.8 cm/yr 
- -2.1 
-1.8 
-2.5 
- - 
Stalvey et al 
(2012) 422 
 
RCT 36 rhGH 
32 Ctrl 
1.0 0.30 9.4 
9.4 
- 8.2 cm/yr 
5.3 cm/yr 
- -1.8 
-1.9 
-1.4 
-1.9 
+0.4 
0.0 
 
Table 9: Published Randomized Trials Of Recombinant Human Growth Hormone On Linear Growth In Children With Cystic Fibrosis 
yrs; years; rhGH: recombinant human growth hormone;Ctrl: control; mg: milligram; kg: kilogram; wk: week; cm; centimetre; HV: height velocity; Ht: height; SDS: standard 
deviation score 
 
